Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A multiple treatment session, open label phase 2 clinical study of GSK2398852 administered following and together with GSK2315698 in cohorts of patients with cardiac amyloidosis

    Summary
    EudraCT number
    2016-000276-23
    Trial protocol
    GB  
    Global end of trial date
    03 Jan 2019

    Results information
    Results version number
    v1(current)
    This version publication date
    12 Oct 2019
    First version publication date
    12 Oct 2019
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    201464
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    GlaxoSmithKline
    Sponsor organisation address
    980 Great West Road, Brentford, Middlesex, United Kingdom,
    Public contact
    GSK Response Center, GlaxoSmithKline, 1 8664357343, GSKClinicalSupportHD@gsk.com
    Scientific contact
    GSK Response Center, GlaxoSmithKline, 1 8664357343, GSKClinicalSupportHD@gsk.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    15 Aug 2019
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    03 Jan 2019
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    - Assessment of reduction in cardiac amyloid load after repeated administrations of Anti-SAP treatment as evaluated by CMR in all study groups - Assessment of safety & tolerability of repeated administration of Anti-SAP treatment, including compatibility with chemotherapy treatment in Group 3
    Protection of trial subjects
    Not applicable
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    10 Jul 2017
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 6
    Country: Number of subjects enrolled
    United States: 1
    Worldwide total number of subjects
    7
    EEA total number of subjects
    6
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    7
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    This was an open label, non-randomized, monthly repeat anti-serum amyloid p component (anti-SAP) treatment study in systemic amyloidosis participants with cardiac dysfunction caused by cardiac amyloidosis.

    Pre-assignment
    Screening details
    Twelve participants were screened; seven were enrolled in to study (six were enrolled in Group 1 and one in Group 2). No participant was enrolled in Group 3. The study was terminated by sponsor due to a change in the benefit:risk profile of GSK2315698+GSK2398852 (anti-SAP treatment).

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants
    Arm description
    Cardiac transthyretin (TTR) amyloidosis (transthyretin amyloid cardiomyopathy [ATTR-CM]) participants with mutant genotypes primarily associated with familial amyloidotic cardiomyopathy (FAC) and wild-type TTR were included. Participants received 6 anti-SAP treatments, consisting of carboxy pyrrolidine hexanoyl pyrrolidine carboxylate (CPHPC) followed by anti-SAP monoclonal antibody (mAb) at monthly intervals. During each anti-SAP treatment, participants received CPHPC intravenous (IV) infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants were administered intravenous infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb was 600 milligrams (mg) (divided into 2 infusions of 300 mg). In each treatment session, CPHPC was administered as subcutaneous (SC) injection for 11 days from the day of first dose of anti-SAP mAb.
    Arm type
    Experimental

    Investigational medicinal product name
    CPHPC IV
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    During each anti-SAP treatments, participants received CPHPC IV infusion once daily for up to 72 hours prior to initial mAb dose.

    Investigational medicinal product name
    CPHPC SC
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    In each treatment session, CPHPC was administered as SC injection for 11 days from the day of first dose of anti-SAP mAb.

    Investigational medicinal product name
    anti-SAP mAb
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Anti-SAP mAb was administered as an IV infusion over 2 days (Days 1 and 3) with 6-8 hour infusion per day. The starting dose level of anti-SAP mAb was 600 mg (divided into 2 infusions of 300 mg).

    Arm title
    Group 2: Post-chemotherapy AL Amyloidosis participants
    Arm description
    Immunoglobin light chain amyloidosis (AL) participants who attained either a very good partial response (VGPR), or complete response (CR), to systemic chemotherapy (including autologous stem cell transplantation) were included. Participants received 6 anti-SAP treatments, consisting of CPHPC followed by anti-SAP mAb at monthly intervals. During each anti-SAP treatment, participants received CPHPC IV infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants were administered IV infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb was 600 mg (divided into 2 infusions of 300 mg). In each treatment session, CPHPC was administered by as SC injection for 11 days from the day of first dose of anti-SAP mAb.
    Arm type
    Experimental

    Investigational medicinal product name
    CPHPC IV
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    During each anti-SAP treatments, participants received CPHPC IV infusion once daily for up to 72 hours prior to initial mAb dose.

    Investigational medicinal product name
    anti-SAP mAb
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Anti-SAP mAb was administered as an IV infusion over 2 days (Days 1 and 3) with 6-8 hour infusion per day. The starting dose level of anti-SAP mAb was 600 mg (divided into 2 infusions of 300 mg).

    Investigational medicinal product name
    CPHPC SC
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    In each treatment session, CPHPC was administered as SC injection for 11 days from the day of first dose of anti-SAP mAb.

    Number of subjects in period 1
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Started
    6
    1
    Completed
    6
    0
    Not completed
    0
    1
         Adverse event, non-fatal
    -
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants
    Reporting group description
    Cardiac transthyretin (TTR) amyloidosis (transthyretin amyloid cardiomyopathy [ATTR-CM]) participants with mutant genotypes primarily associated with familial amyloidotic cardiomyopathy (FAC) and wild-type TTR were included. Participants received 6 anti-SAP treatments, consisting of carboxy pyrrolidine hexanoyl pyrrolidine carboxylate (CPHPC) followed by anti-SAP monoclonal antibody (mAb) at monthly intervals. During each anti-SAP treatment, participants received CPHPC intravenous (IV) infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants were administered intravenous infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb was 600 milligrams (mg) (divided into 2 infusions of 300 mg). In each treatment session, CPHPC was administered as subcutaneous (SC) injection for 11 days from the day of first dose of anti-SAP mAb.

    Reporting group title
    Group 2: Post-chemotherapy AL Amyloidosis participants
    Reporting group description
    Immunoglobin light chain amyloidosis (AL) participants who attained either a very good partial response (VGPR), or complete response (CR), to systemic chemotherapy (including autologous stem cell transplantation) were included. Participants received 6 anti-SAP treatments, consisting of CPHPC followed by anti-SAP mAb at monthly intervals. During each anti-SAP treatment, participants received CPHPC IV infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants were administered IV infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb was 600 mg (divided into 2 infusions of 300 mg). In each treatment session, CPHPC was administered by as SC injection for 11 days from the day of first dose of anti-SAP mAb.

    Reporting group values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants Total
    Number of subjects
    6 1 7
    Age categorical
    Units: Subjects
        Total participants
    6 1 7
    Age Continuous
    '99' or '99999' indicates data was not available.
    Units: years
        arithmetic mean (standard deviation)
    74.3 ( 3.27 ) 67.0 ( 99999 ) -
    Sex: Female, Male
    Units: Subjects
        Female
    0 0 0
        Male
    6 1 7
    Race/Ethnicity, Customized
    Units: Subjects
        White/Caucasian/European Heritage
    6 1 7

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants
    Reporting group description
    Cardiac transthyretin (TTR) amyloidosis (transthyretin amyloid cardiomyopathy [ATTR-CM]) participants with mutant genotypes primarily associated with familial amyloidotic cardiomyopathy (FAC) and wild-type TTR were included. Participants received 6 anti-SAP treatments, consisting of carboxy pyrrolidine hexanoyl pyrrolidine carboxylate (CPHPC) followed by anti-SAP monoclonal antibody (mAb) at monthly intervals. During each anti-SAP treatment, participants received CPHPC intravenous (IV) infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants were administered intravenous infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb was 600 milligrams (mg) (divided into 2 infusions of 300 mg). In each treatment session, CPHPC was administered as subcutaneous (SC) injection for 11 days from the day of first dose of anti-SAP mAb.

    Reporting group title
    Group 2: Post-chemotherapy AL Amyloidosis participants
    Reporting group description
    Immunoglobin light chain amyloidosis (AL) participants who attained either a very good partial response (VGPR), or complete response (CR), to systemic chemotherapy (including autologous stem cell transplantation) were included. Participants received 6 anti-SAP treatments, consisting of CPHPC followed by anti-SAP mAb at monthly intervals. During each anti-SAP treatment, participants received CPHPC IV infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants were administered IV infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb was 600 mg (divided into 2 infusions of 300 mg). In each treatment session, CPHPC was administered by as SC injection for 11 days from the day of first dose of anti-SAP mAb.

    Primary: Change from Baseline in left ventricular (LV) mass over time up to 8-week follow-up

    Close Top of page
    End point title
    Change from Baseline in left ventricular (LV) mass over time up to 8-week follow-up [1]
    End point description
    Left ventricular mass was measured by Cardiac Magnetic Resonance (CMR) imaging to assess reduction in cardiac amyloid load after repeated administration of anti-SAP treatment. Each CMR imaging session took approximately 45-60 minutes, with a maximum scan time inside of the scanner of 90 minutes. Baseline was considered as the latest assessment prior to first administration of either study drug, i.e. CPHPC or anti-SAP mAb. Change from Baseline was calculated as post-dose visit value minus Baseline value. Safety Population comprised of all participants who received at least one dose of study treatment (any dose of CPHPC [GSK2315698] or anti-SAP mAb [GSK2398852]). Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. 88888 indicates data is not available as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Primary
    End point timeframe
    Baseline (Day -1) and Session 2 Day 24, Session 3 Day 24, Session 4 Day 24, Session 5 Day 24, 8 Weeks Follow-up
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: There are no statistical data to report.
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [2]
    1 [3]
    Units: Grams
    arithmetic mean (standard deviation)
        Session 2, Day 24, n=6,0
    2.505 ( 19.9174 )
    99999 ( 99999 )
        Session 3, Day 24, n=6,0
    4.175 ( 22.9366 )
    99999 ( 99999 )
        Session 4, Day 24, n=5,0
    9.194 ( 14.4271 )
    99999 ( 99999 )
        Session 5, Day 24, n=4,0
    7.955 ( 19.4341 )
    99999 ( 99999 )
        8 Weeks Follow up, n=6,1
    0.977 ( 12.1795 )
    -32.420 ( 88888 )
    Notes
    [2] - Safety Population
    [3] - Safety Population
    No statistical analyses for this end point

    Primary: Number of participants with any on-treatment adverse events (AEs)

    Close Top of page
    End point title
    Number of participants with any on-treatment adverse events (AEs) [4]
    End point description
    AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with any on-treatment AEs are presented.
    End point type
    Primary
    End point timeframe
    Up to 56 days after the last dosing session (up to 265 days)
    Notes
    [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: There are no statistical data to report.
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [5]
    1 [6]
    Units: Participants
    6
    1
    Notes
    [5] - Safety Population
    [6] - Safety Population
    No statistical analyses for this end point

    Primary: Number of participants with any serious adverse events (SAEs)

    Close Top of page
    End point title
    Number of participants with any serious adverse events (SAEs) [7]
    End point description
    AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, events associated with liver injury and impaired liver function, or any other situation according to medical or scientific judgment were categorized as SAE. Number of participants with any SAEs during study are presented.
    End point type
    Primary
    End point timeframe
    Up to the end of study (Up to 369 days)
    Notes
    [7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: There are no statistical data to report.
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [8]
    1 [9]
    Units: Participants
    2
    1
    Notes
    [8] - Safety Population
    [9] - Safety Population
    No statistical analyses for this end point

    Primary: Number of participants with abnormal hematology values

    Close Top of page
    End point title
    Number of participants with abnormal hematology values [10]
    End point description
    Blood samples were collected for assessment of hematology parameters, which included platelet count, hemoglobin, hematocrit, erythrocytes, reticulocyte count, Mean corpuscular volume (MCV), Mean corpuscular hemoglobin (MCH), Mean corpuscular hemoglobin concentration (MCHC), neutrophils, lymphocytes, monocytes, eosinophils, leukocytes and basophils. Abnormal laboratory results are categorized as high, low or normal with respect to their normal ranges. Data for worst case post Baseline is presented. Participants having both High and Low values from Normal Ranges at any post-baseline visits for any parameter was counted in both the High and Low categories.
    End point type
    Primary
    End point timeframe
    Up to the end of study (Up to 369 days)
    Notes
    [10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: There are no statistical data to report.
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [11]
    1 [12]
    Units: Participants
        Basophils, high
    2
    0
        Basophils, normal
    4
    1
        Basophils, low
    0
    0
        Eosinophils, high
    3
    0
        Eosinophils, normal
    3
    1
        Eosinophils, low
    0
    0
        Hematocrit, high
    0
    0
        Hematocrit, normal
    1
    0
        Hematocrit, low
    5
    1
        Hemoglobin, high
    0
    0
        Hemoglobin, normal
    0
    0
        Hemoglobin, low
    6
    1
        Lymphocytes, high
    1
    0
        Lymphocytes, normal
    0
    0
        Lymphocytes, low
    6
    1
        MCH, high
    1
    0
        MCH, normal
    3
    1
        MCH, low
    3
    0
        MCHC, high
    3
    0
        MCHC, normal
    1
    1
        MCHC, low
    2
    0
        MCV, high
    1
    0
        MCV, normal
    4
    1
        MCV, low
    2
    0
        Monocytes, high
    2
    1
        Monocytes, normal
    4
    0
        Monocytes, low
    0
    0
        Neutrophils, high
    5
    1
        Neutrophils, normal
    0
    0
        Neutrophils, low
    4
    0
        Platelet count, high
    1
    0
        Platelet count, normal
    3
    0
        Platelet count, low
    2
    1
        Erythrocytes, high
    0
    0
        Erythrocytes, normal
    0
    0
        Erythrocytes, low
    6
    1
        Reticulocytes, high
    1
    0
        Reticulocytes, normal
    5
    1
        Reticulocytes, low
    0
    0
        Leukocytes, high
    2
    1
        Leukocytes, normal
    3
    0
        Leukocytes, low
    1
    0
    Notes
    [11] - Safety Population
    [12] - Safety Population
    No statistical analyses for this end point

    Primary: Number of participants with abnormal clinical chemistry values

    Close Top of page
    End point title
    Number of participants with abnormal clinical chemistry values [13]
    End point description
    Blood samples were collected for assessment of clinical chemistry parameters, which included aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), urea, creatinine, glucose, chloride, creatinine kinase, potassium, sodium, calcium, total carbon dioxide (CO2), urate, total and direct bilirubin, total protein and albumin. Abnormal laboratory results are categorized as high, low or normal with respect to their normal ranges. Data for worst case post Baseline is presented. Participants having both High and Low values from Normal Ranges at any post-baseline visits for any parameter was counted in both the High and Low categories.
    End point type
    Primary
    End point timeframe
    Up to the end of study (Up to 369 days)
    Notes
    [13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: There are no statistical data to report.
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [14]
    1 [15]
    Units: Participants
        Glucose, high
    6
    1
        Glucose, normal
    0
    0
        Glucose, low
    0
    0
        Albumin, high
    0
    0
        Albumin, normal
    2
    1
        Albumin, low
    4
    0
        ALP, high
    5
    0
        ALP, normal
    1
    1
        ALP, low
    0
    0
        ALT, high
    2
    1
        ALT, normal
    4
    0
        ALT, low
    0
    0
        AST, high
    4
    1
        AST, normal
    2
    0
        AST, low
    0
    0
        Direct Bilirubin, high
    4
    1
        Direct Bilirubin, normal
    2
    0
        Direct Bilirubin, low
    0
    0
        Total Bilirubin, high
    4
    0
        Total Bilirubin, normal
    2
    1
        Total Bilirubin, low
    0
    0
        Calcium, high
    0
    0
        Calcium, normal
    4
    0
        Calcium, low
    2
    1
        Creatinine Kinase, high
    1
    0
        Creatinine Kinase, normal
    3
    1
        Creatinine Kinase, low
    2
    0
        Chloride, high
    0
    0
        Chloride, normal
    1
    0
        Chloride, low
    5
    1
        CO2, high
    6
    0
        CO2, normal
    0
    1
        CO2, low
    4
    0
        Creatinine, high
    4
    0
        Creatinine, normal
    2
    1
        Creatinine, low
    0
    0
        Potassium, high
    2
    0
        Potassium, normal
    3
    1
        Potassium, low
    2
    0
        LDH, high
    6
    1
        LDH, normal
    0
    0
        LDH, low
    0
    0
        Protein, high
    0
    0
        Protein, normal
    0
    0
        Protein, low
    6
    1
        Sodium, high
    1
    0
        Sodium, normal
    5
    1
        Sodium, low
    0
    0
        Urate, high
    5
    1
        Urate, normal
    1
    0
        Urate, low
    0
    0
        Urea, high
    6
    1
        Urea, normal
    0
    0
        Urea, low
    0
    0
    Notes
    [14] - Safety Population
    [15] - Safety Population
    No statistical analyses for this end point

    Primary: Number of participants with abnormal urinalysis results

    Close Top of page
    End point title
    Number of participants with abnormal urinalysis results [16]
    End point description
    Urine samples were collected to assess potential of hydrogen (pH), specific gravity, albumin excretion rate, creatinine excretion rate and protein excretion rate. Abnormal urinalysis results are categorized as high, low or normal with respect to their normal ranges. Data for worst case post Baseline is presented. Participants having both High and Low values from Normal Ranges at any post-baseline visits for any parameter was counted in both the High and Low categories. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available.
    End point type
    Primary
    End point timeframe
    Up to the end of study (Up to 369 days)
    Notes
    [16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: There are no statistical data to report.
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [17]
    1 [18]
    Units: Participants
        pH, high, n=6,1
    0
    0
        pH, normal, n=6,1
    6
    1
        pH, low, n=6,1
    0
    0
        Specific gravity, high, n=1,0
    0
    99999
        Specific gravity, normal, n=1,0
    1
    99999
        Specific gravity, low, n=1,0
    0
    99999
        Albumin excretion rate, high, n=6,1
    0
    0
        Albumin excretion rate, normal, n=6,1
    6
    1
        Albumin excretion rate, low, n=6,1
    0
    0
        Creatinine excretion rate, high, n=6,1
    1
    0
        Creatinine excretion rate, normal, n=6,1
    1
    1
        Creatinine excretion rate, low, n=6,1
    5
    0
        Protein excretion rate, high, n=6,1
    4
    1
        Protein excretion rate, normal, n=6,1
    2
    0
        Protein excretion rate, low, n=6,1
    0
    0
    Notes
    [17] - Safety Population
    [18] - Safety Population
    No statistical analyses for this end point

    Primary: Number of participants with abnormal urinalysis results for character parameters

    Close Top of page
    End point title
    Number of participants with abnormal urinalysis results for character parameters [19]
    End point description
    Urine samples were collected to assess character parameters which included Cellular Casts, Erythrocytes, Glucose, Ketones, Leukocytes and Occult Blood. Number of participants with abnormal urinalysis results are presented. Data for worst case post Baseline is presented. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).
    End point type
    Primary
    End point timeframe
    Up to the end of study (Up to 369 days)
    Notes
    [19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: There are no statistical data to report.
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [20]
    1 [21]
    Units: Participants
        Cellular casts, n=5,1
    0
    0
        Erythrocytes , n=6,1
    6
    1
        Glucose, n=6,1
    1
    0
        Ketones, n=6,1
    0
    0
        Leukocytes, n=6,1
    6
    1
        Occult blood, n=6,1
    2
    1
    Notes
    [20] - Safety Population
    [21] - Safety Population
    No statistical analyses for this end point

    Primary: Number of participants with body temperature shifts from Baseline relative to potential clinical importance (PCI) criteria

    Close Top of page
    End point title
    Number of participants with body temperature shifts from Baseline relative to potential clinical importance (PCI) criteria [22]
    End point description
    Vital signs including body temperature was measured after participants rested in semi-supine position for at least 5 minutes. Number of participants with shifts in body temperature from Baseline to worst case post Baseline relative to PCI criteria have been presented. PCI results were categorized as to high, to low and to normal/no change with reference to PCI criteria. PCI criteria for body temperature was: high: >37.5 degree Celsius; low: not applicable.
    End point type
    Primary
    End point timeframe
    Up to the end of study (Up to 369 days)
    Notes
    [22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: There are no statistical data to report.
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [23]
    1 [24]
    Units: Participants
        To high
    2
    0
        To normal/No change
    4
    1
        To low
    0
    0
    Notes
    [23] - Safety Population
    [24] - Safety Population
    No statistical analyses for this end point

    Primary: Number of participants with systolic blood pressure (SBP) and diastolic blood pressure (DBP) shifts from Baseline relative to PCI criteria

    Close Top of page
    End point title
    Number of participants with systolic blood pressure (SBP) and diastolic blood pressure (DBP) shifts from Baseline relative to PCI criteria [25]
    End point description
    Vital signs including SBP and DBP were measured after participants rested in semi-supine position for at least 5 minutes. Number of participants with shifts in SBP and DBP from baseline to worst case post baseline relative to PCI criteria have been presented. PCI results were categorized as to high, to low and to normal/no change with reference to PCI criteria. PCI criteria for SBP was: high: >180 millimeter of mercury (mmHg); low: <90 mmHg. PCI criteria for DBP was: high: >110 mmHg; low: <30 mmHg.
    End point type
    Primary
    End point timeframe
    Up to the end of study (Up to 369 days)
    Notes
    [25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: There are no statistical data to report.
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [26]
    1 [27]
    Units: Participants
        SBP, To high
    0
    0
        SBP, To normal/No change
    1
    1
        SBP, To low
    5
    0
        DBP, To high
    0
    0
        DBP, To normal/No change
    6
    1
        DBP, To low
    0
    0
    Notes
    [26] - Safety Population
    [27] - Safety Population
    No statistical analyses for this end point

    Primary: Number of participants with pulse rate shifts from Baseline relative to PCI criteria

    Close Top of page
    End point title
    Number of participants with pulse rate shifts from Baseline relative to PCI criteria [28]
    End point description
    Vital signs including pulse rate were measured after participants rested in semi-supine position for at least 5 minutes. Number of participants with shifts in pulse rate from baseline to worst case post baseline relative to PCI criteria have been presented. PCI results were categorized as to high, to low and to normal/no change with reference to its PCI criteria. PCI criteria for pulse rate was: high: >140 beats per minute (bpm); low: <35 bpm.
    End point type
    Primary
    End point timeframe
    Up to the end of study (Up to 369 days)
    Notes
    [28] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: There are no statistical data to report.
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [29]
    1 [30]
    Units: Participants
        To high
    0
    0
        To normal/No change
    6
    1
        To low
    0
    0
    Notes
    [29] - Safety Population
    [30] - Safety Population
    No statistical analyses for this end point

    Primary: Number of participants with abnormal electrocardiogram (ECG) findings

    Close Top of page
    End point title
    Number of participants with abnormal electrocardiogram (ECG) findings [31]
    End point description
    Twelve-lead ECGs were performed during the study using an automated ECG machine. The number of participants with worst case post-Baseline abnormal ECG findings were reported and categorized as abnormal-clinically significant and abnormal-not clinically significant.
    End point type
    Primary
    End point timeframe
    Up to the end of study (Up to 369 days)
    Notes
    [31] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: There are no statistical data to report.
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [32]
    1 [33]
    Units: Participants
        Abnormal-Clinically significant
    0
    0
        Abnormal-Not Clinically significant
    6
    1
    Notes
    [32] - Safety Population
    [33] - Safety Population
    No statistical analyses for this end point

    Primary: Number of participants with abnormalities during cardiac monitoring

    Close Top of page
    End point title
    Number of participants with abnormalities during cardiac monitoring [34]
    End point description
    Lead II telemetry and cardiac monitoring devices were used for electrical cardiac monitoring during the study. The number of participants with worst case post-Baseline abnormalities during cardiac monitoring as per investigator's assessment have been reported and categorized as Abnormal-clinically significant and Abnormal-not clinically significant. Only those participants with data available at the specified time point was analyzed.
    End point type
    Primary
    End point timeframe
    Up to the end of study (Up to 369 days)
    Notes
    [34] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: There are no statistical data to report.
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    5 [35]
    1 [36]
    Units: Participants
        Abnormal-Clinically significant
    2
    0
        Abnormal-Not Clinically significant
    3
    1
    Notes
    [35] - Safety Population
    [36] - Safety Population
    No statistical analyses for this end point

    Primary: Number of participants for which unscheduled echocardiography (ECHO) was performed for safety reasons

    Close Top of page
    End point title
    Number of participants for which unscheduled echocardiography (ECHO) was performed for safety reasons [37]
    End point description
    Echocardiography was performed by a qualified echocardiographer or cardiologist during the study. Number of participants with unscheduled echocardiograms performed for safety reasons have been presented. Only those participants with data available at the specified time point was analyzed.
    End point type
    Primary
    End point timeframe
    Up to the end of study (Up to 369 days)
    Notes
    [37] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: There are no statistical data to report.
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    2 [38]
    0 [39]
    Units: Participants
    2
    Notes
    [38] - Safety Population
    [39] - Safety Population
    No statistical analyses for this end point

    Primary: Number of participants with skin rashes

    Close Top of page
    End point title
    Number of participants with skin rashes [40]
    End point description
    Skin rash was an event of special interest. Only Rashes that were associated with study drug were categorised as Rash for Common Terminology Criteria for Adverse Events (CTCAE) and are presented. Number of participants with on-treatment skin rash AEs are presented.
    End point type
    Primary
    End point timeframe
    Up to 56 days after the last dosing session (up to 265 days)
    Notes
    [40] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: There are no statistical data to report.
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [41]
    1 [42]
    Units: Participants
    4
    0
    Notes
    [41] - Safety Population
    [42] - Safety Population
    No statistical analyses for this end point

    Primary: Number of participants with skin rashes classified using CTCAE

    Close Top of page
    End point title
    Number of participants with skin rashes classified using CTCAE [43]
    End point description
    Skin rash was an event of special interest. All the events of rashes were graded for their severity using CTCAE version 4.0 . Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life threatening, Grade 5: death. Higher the grade, more severe the symptoms. Only Rashes that were associated with study drug were categorized as Rash for CTCAE and are presented here. Number of participants with skin rashes classified by their maximum grade are presented.
    End point type
    Primary
    End point timeframe
    Up to 56 days after the last dosing session (up to 265 days)
    Notes
    [43] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: There are no statistical data to report.
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    4 [44]
    0 [45]
    Units: Participants
        Grade 1
    3
        Grade 2
    1
        Grade 3
    0
        Grade 4
    0
        Grade 5
    0
    Notes
    [44] - Safety Population
    [45] - Safety Population
    No statistical analyses for this end point

    Secondary: Number of participants with abnormalities in histopathological examination of skin biopsies

    Close Top of page
    End point title
    Number of participants with abnormalities in histopathological examination of skin biopsies
    End point description
    Skin biopsy samples were collected for histopathological examination only on any rash development (>= Grade 1) as decided by clinical judgment of the Investigator and/or dermatologist. Number of participants with abnormalities in histopathological examination of skin biopsies are presented.
    End point type
    Secondary
    End point timeframe
    Up to the end of study (Up to 369 days)
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [46]
    1 [47]
    Units: Participants
    2
    0
    Notes
    [46] - Safety Population
    [47] - Safety Population
    No statistical analyses for this end point

    Secondary: Number of participants with abnormalities in immunohistochemical examination of skin biopsies

    Close Top of page
    End point title
    Number of participants with abnormalities in immunohistochemical examination of skin biopsies
    End point description
    Skin biopsy samples were collected for immunohistochemical examination only on any rash development (>= Grade 1) as decided by clinical judgment of the Investigator and/or dermatologist. Number of participants with abnormalities in immunohistochemical examination of skin biopsies are presented.
    End point type
    Secondary
    End point timeframe
    Up to the end of study (Up to 369 days)
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [48]
    1 [49]
    Units: Participants
    2
    1
    Notes
    [48] - Safety Population
    [49] - Safety Population
    No statistical analyses for this end point

    Secondary: Number of participants with abnormalities in histopathological examination of blood biomarkers

    Close Top of page
    End point title
    Number of participants with abnormalities in histopathological examination of blood biomarkers
    End point description
    Blood samples were to be collected along with each skin biopsy sample for histopathological examination of blood biomarkers only on any rash development (>= Grade 1) as decided by clinical judgment of the Investigator and/or dermatologist. Data was not collected due to project termination.
    End point type
    Secondary
    End point timeframe
    Up to the end of study (Up to 369 days)
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    0 [50]
    0 [51]
    Units: Participants
    Notes
    [50] - Safety Population
    [51] - Safety Population
    No statistical analyses for this end point

    Secondary: Number of participants with abnormalities in immunohistochemical examination of blood biomarkers

    Close Top of page
    End point title
    Number of participants with abnormalities in immunohistochemical examination of blood biomarkers
    End point description
    Blood samples were to be collected along with each skin biopsy sample for immunohistochemical examination of blood biomarkers only on any rash development (>= Grade 1) as decided by clinical judgment of the Investigator and/or dermatologist. Data was not collected due to project termination.
    End point type
    Secondary
    End point timeframe
    Up to the end of study (Up to 369 days)
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    0 [52]
    0 [53]
    Units: Participants
    Notes
    [52] - Safety Population
    [53] - Safety Population
    No statistical analyses for this end point

    Secondary: Change from Baseline in Fluid Phase Complement Marker-Complement 3 (C3) over time

    Close Top of page
    End point title
    Change from Baseline in Fluid Phase Complement Marker-Complement 3 (C3) over time
    End point description
    Blood samples were collected for assessment of Fluid Phase Complement Markers which included complement 3 (C3). Baseline was considered as the latest assessment prior to first administration of either study drug, i.e. CPHPC or anti-SAP mAb. Change from Baseline was calculated as post-dose visit value minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).99999 indicates data is not available. 88888 indicates data is not available, as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -1) and Session 1 to 6: Day 1 (predose, 2,4,8 hours), Day 2, Day 3 (predose, 2,4,8 hours), Day 5, Day 6
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [54]
    1 [55]
    Units: Grams per Liter (g/L)
    arithmetic mean (standard deviation)
        C3, Session 1, Day 1, predose, n=6,1
    -0.032 ( 0.1444 )
    -0.150 ( 88888 )
        C3, Session 1, Day 1, 2 hour, n=6,1
    -0.008 ( 0.1105 )
    -0.230 ( 88888 )
        C3, Session 1, Day 1, 4 hour, n=6,1
    0.030 ( 0.0566 )
    -0.100 ( 88888 )
        C3, Session 1, Day 1, 8 hour, n=6,1
    0.068 ( 0.2073 )
    -0.160 ( 88888 )
        C3, Session 1, Day 2, n=6,1
    -0.125 ( 0.1033 )
    -0.180 ( 88888 )
        C3, Session 1, Day 3, predose, n=6,1
    -0.198 ( 0.1607 )
    -0.200 ( 88888 )
        C3, Session 1, Day 3, 2 hour, n=6,0
    -0.188 ( 0.1572 )
    99999 ( 99999 )
        C3, Session 1, Day 3, 4 hour, n=6,0
    -0.222 ( 0.1288 )
    99999 ( 99999 )
        C3, Session 1, Day 3, 8 hour, n=6,0
    -0.155 ( 0.1590 )
    99999 ( 99999 )
        C3, Session 1, Day 5, n=6,0
    -0.280 ( 0.1646 )
    99999 ( 99999 )
        C3, Session 1, Day 6, n=6,0
    -0.338 ( 0.1969 )
    99999 ( 99999 )
        C3, Session 2, Day 1, predose, n=6,0
    -0.067 ( 0.1999 )
    99999 ( 99999 )
        C3, Session 2, Day 1, 2 hour, n=6,0
    -0.103 ( 0.1629 )
    99999 ( 99999 )
        C3, Session 2, Day 1, 4 hour, n=6,0
    -0.075 ( 0.2017 )
    99999 ( 99999 )
        C3, Session 2, Day 1, 8 hour, n=6,0
    -0.130 ( 0.1585 )
    99999 ( 99999 )
        C3, Session 2, Day 2, n=6,0
    -0.153 ( 0.1485 )
    99999 ( 99999 )
        C3, Session 2, Day 3, predose, n=6,0
    -0.263 ( 0.1385 )
    99999 ( 99999 )
        C3, Session 2, Day 3, 2 hour, n=6,0
    -0.242 ( 0.1694 )
    99999 ( 99999 )
        C3, Session 2, Day 3, 4 hour, n=6,0
    -0.243 ( 0.1994 )
    99999 ( 99999 )
        C3, Session 2, Day 3, 8 hour, n=6,0
    -0.235 ( 0.1685 )
    99999 ( 99999 )
        C3, Session 2, Day 5, n=6,0
    -0.280 ( 0.1716 )
    99999 ( 99999 )
        C3, Session 2, Day 6, n=6,0
    -0.327 ( 0.2298 )
    99999 ( 99999 )
        C3, Session 3, Day 1, predose, n=6,0
    -0.053 ( 0.1928 )
    99999 ( 99999 )
        C3, Session 3, Day 1, 2 hour, n=6,0
    -0.078 ( 0.2279 )
    99999 ( 99999 )
        C3, Session 3, Day 1, 4 hour, n=6,0
    -0.058 ( 0.2299 )
    99999 ( 99999 )
        C3, Session 3, Day 1, 8 hour, n=6,0
    -0.057 ( 0.1999 )
    99999 ( 99999 )
        C3, Session 3, Day 2, n=5,0
    -0.084 ( 0.2792 )
    99999 ( 99999 )
        C3, Session 3, Day 3, predose, n=6,0
    -0.215 ( 0.1576 )
    99999 ( 99999 )
        C3, Session 3, Day 3, 2 hour, n=6,0
    -0.232 ( 0.1699 )
    99999 ( 99999 )
        C3, Session 3, Day 3, 4 hour, n=6,0
    -0.200 ( 0.1808 )
    99999 ( 99999 )
        C3, Session 3, Day 3, 8 hour, n=6,0
    -0.190 ( 0.2287 )
    99999 ( 99999 )
        C3, Session 3, Day 5, n=6,0
    -0.290 ( 0.1719 )
    99999 ( 99999 )
        C3, Session 3, Day 6, n=6,0
    -0.308 ( 0.2077 )
    99999 ( 99999 )
        C3, Session 4, Day 1, predose, n=5,0
    -0.094 ( 0.2271 )
    99999 ( 99999 )
        C3, Session 4, Day 1, 2 hour, n=5,0
    -0.088 ( 0.1993 )
    99999 ( 99999 )
        C3, Session 4, Day 1, 4 hour, n=4,0
    -0.005 ( 0.1392 )
    99999 ( 99999 )
        C3, Session 4, Day 1, 8 hour, n=5,0
    -0.124 ( 0.1747 )
    99999 ( 99999 )
        C3, Session 4, Day 2, n=5,0
    -0.144 ( 0.1641 )
    99999 ( 99999 )
        C3, Session 4, Day 3, predose, n=5,0
    -0.214 ( 0.2454 )
    99999 ( 99999 )
        C3, Session 4, Day 3, 2 hour, n=5,0
    -0.204 ( 0.2306 )
    99999 ( 99999 )
        C3, Session 4, Day 3, 4 hour, n=5,0
    -0.190 ( 0.2088 )
    99999 ( 99999 )
        C3, Session 4, Day 3, 8 hour, n=5,0
    -0.188 ( 0.2305 )
    99999 ( 99999 )
        C3, Session 4, Day 5, n=5,0
    -0.270 ( 0.1996 )
    99999 ( 99999 )
        C3, Session 4, Day 6, n=5,0
    -0.302 ( 0.2251 )
    99999 ( 99999 )
        C3, Session 5, Day 1, predose, n=4,0
    -0.173 ( 0.1863 )
    99999 ( 99999 )
        C3, Session 5, Day 1, 2 hour, n=4,0
    -0.147 ( 0.2326 )
    99999 ( 99999 )
        C3, Session 5, Day 1, 4 hour, n=4,0
    -0.125 ( 0.1741 )
    99999 ( 99999 )
        C3, Session 5, Day 1, 8 hour, n=4,0
    -0.150 ( 0.1881 )
    99999 ( 99999 )
        C3, Session 5, Day 2, n=4,0
    -0.178 ( 0.2340 )
    99999 ( 99999 )
        C3, Session 5, Day 3, predose, n=4,0
    -0.248 ( 0.1919 )
    99999 ( 99999 )
        C3, Session 5, Day 3, 2 hour, n=4,0
    -0.235 ( 0.1964 )
    99999 ( 99999 )
        C3, Session 5, Day 3, 4 hour, n=4,0
    -0.280 ( 0.2045 )
    99999 ( 99999 )
        C3, Session 5, Day 3, 8 hour, n=4,0
    -0.235 ( 0.2301 )
    99999 ( 99999 )
        C3, Session 5, Day 5, n=4,0
    -0.258 ( 0.2035 )
    99999 ( 99999 )
        C3, Session 5, Day 6, n=4,0
    -0.288 ( 0.1941 )
    99999 ( 99999 )
        C3, Session 6, Day 1, predose, n=4,0
    -0.152 ( 0.2144 )
    99999 ( 99999 )
        C3, Session 6, Day 1, 2 hour, n=4,0
    -0.145 ( 0.1877 )
    99999 ( 99999 )
        C3, Session 6, Day 1, 4 hour, n=4,0
    -0.145 ( 0.2528 )
    99999 ( 99999 )
        C3, Session 6, Day 1, 8 hour, n=4,0
    -0.135 ( 0.2626 )
    99999 ( 99999 )
        C3, Session 6, Day 2, n=4,0
    -0.203 ( 0.2090 )
    99999 ( 99999 )
        C3, Session 6, Day 3, predose, n=4,0
    -0.215 ( 0.2319 )
    99999 ( 99999 )
        C3, Session 6, Day 3, 2 hour, n=4,0
    -0.273 ( 0.2179 )
    99999 ( 99999 )
        C3, Session 6, Day 3, 4 hour, n=4,0
    -0.235 ( 0.2243 )
    99999 ( 99999 )
        C3, Session 6, Day 3, 8 hour, n=4,0
    -0.238 ( 0.2421 )
    99999 ( 99999 )
        C3, Session 6, Day 5, n=4,0
    -0.288 ( 0.2269 )
    99999 ( 99999 )
        C3, Session 6, Day 6, n=4,0
    -0.315 ( 0.2225 )
    99999 ( 99999 )
    Notes
    [54] - Safety Population
    [55] - Safety Population
    No statistical analyses for this end point

    Secondary: Change from Baseline in Fluid Phase Complement Marker-Complement 4 (C4) over time

    Close Top of page
    End point title
    Change from Baseline in Fluid Phase Complement Marker-Complement 4 (C4) over time
    End point description
    Blood samples were collected for assessment of Fluid Phase Complement Markers which included complement 4 (C4). Baseline was considered as the latest assessment prior to first administration of either study drug, i.e. CPHPC or anti-SAP mAb. Change from Baseline was calculated as post-dose visit value minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. 88888 indicates data is not available, as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -1) and Day 2, Day 5, Day 6
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [56]
    1 [57]
    Units: Grams per Liter (g/L)
    arithmetic mean (standard deviation)
        C4, Session 1, Day 2, n=6,1
    -0.015 ( 0.0373 )
    0.000 ( 88888 )
        C4, Session 1, Day 5, n=6,0
    -0.013 ( 0.0393 )
    99999 ( 99999 )
        C4, Session 1, Day 6, n=6,0
    -0.017 ( 0.0403 )
    99999 ( 99999 )
        C4, Session 2, Day 2, n=6,0
    -0.027 ( 0.0423 )
    99999 ( 99999 )
        C4, Session 2, Day 5, n=6,0
    -0.023 ( 0.0505 )
    99999 ( 99999 )
        C4, Session 2, Day 6, n=6,0
    -0.030 ( 0.0540 )
    99999 ( 99999 )
        C4, Session 3, Day 2, n=5,0
    -0.010 ( 0.0543 )
    99999 ( 99999 )
        C4, Session 3, Day 5, n=6,0
    -0.042 ( 0.0449 )
    99999 ( 99999 )
        C4, Session 3, Day 6, n=6,0
    -0.042 ( 0.0542 )
    99999 ( 99999 )
        C4, Session 4, Day 2, n=5,0
    -0.022 ( 0.0531 )
    99999 ( 99999 )
        C4, Session 4, Day 5, n=5,0
    -0.036 ( 0.0677 )
    99999 ( 99999 )
        C4, Session 4, Day 6, n=5,0
    -0.042 ( 0.0507 )
    99999 ( 99999 )
        C4, Session 5, Day 2, n=4,0
    -0.028 ( 0.0574 )
    99999 ( 99999 )
        C4, Session 5, Day 5, n=4,0
    -0.033 ( 0.0574 )
    99999 ( 99999 )
        C4, Session 5, Day 6, n=4,0
    -0.025 ( 0.0545 )
    99999 ( 99999 )
        C4, Session 6, Day 2, n=4,0
    -0.043 ( 0.0544 )
    99999 ( 99999 )
        C4, Session 6, Day 5, n=4,0
    -0.050 ( 0.0678 )
    99999 ( 99999 )
        C4, Session 6, Day 6, n=4,0
    -0.045 ( 0.0666 )
    99999 ( 99999 )
    Notes
    [56] - Safety Population
    [57] - Safety Population
    No statistical analyses for this end point

    Secondary: Change from Baseline in Fluid Phase Complement Marker-Total Complement (CH50) over time

    Close Top of page
    End point title
    Change from Baseline in Fluid Phase Complement Marker-Total Complement (CH50) over time
    End point description
    Blood samples were collected for assessment of Fluid Phase Complement Markers which included total complement (CH50). Baseline was considered as the latest assessment prior to first administration of either study drug, i.e. CPHPC or anti-SAP mAb. Change from Baseline was calculated as post-dose visit value minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. 88888 indicates data is not available, as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -1) and Session 1 to 6: Day 1 (predose, 2,4,8 hours), Day 2, Day 3 (predose, 2,4,8 hours), Day 5, Day 6
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [58]
    1 [59]
    Units: Units per milliliter
    arithmetic mean (standard deviation)
        CH50, Session 1, Day 1, predose, n=6,1
    -0.7 ( 1.37 )
    0.0 ( 88888 )
        CH50, Session 1, Day 1, 2 hour, n=6,1
    -0.8 ( 1.33 )
    0.0 ( 88888 )
        CH50, Session 1, Day 1, 4 hour, n=6,1
    0.2 ( 0.41 )
    0.0 ( 88888 )
        CH50, Session 1, Day 1, 8 hour, n=6,1
    -0.8 ( 1.60 )
    0.0 ( 88888 )
        CH50, Session 1, Day 2, n=6,1
    -2.7 ( 3.20 )
    0.0 ( 88888 )
        CH50, Session 1, Day 3, predose, n=6,1
    -3.3 ( 4.46 )
    0.0 ( 88888 )
        CH50, Session 1, Day 3, 2 hour, n=6,0
    -3.3 ( 4.37 )
    99999 ( 99999 )
        CH50, Session 1, Day 3, 4 hour, n=6,0
    -2.5 ( 3.78 )
    99999 ( 99999 )
        CH50, Session 1, Day 3, 8 hour, n=6,0
    -2.2 ( 3.25 )
    99999 ( 99999 )
        CH50, Session 1, Day 5, n=6,0
    -4.7 ( 5.01 )
    99999 ( 99999 )
        CH50, Session 1, Day 6, n=6,0
    -7.3 ( 6.19 )
    99999 ( 99999 )
        CH50, Session 2, Day 1, predose, n=6,0
    -1.7 ( 3.67 )
    99999 ( 99999 )
        CH50, Session 2, Day 1, 2 hour, n=6,0
    -2.3 ( 4.84 )
    99999 ( 99999 )
        CH50, Session 2, Day 1, 4 hour, n=6,0
    -2.3 ( 4.63 )
    99999 ( 99999 )
        CH50, Session 2, Day 1, 8 hour, n=6,0
    -3.5 ( 7.84 )
    99999 ( 99999 )
        CH50, Session 2, Day 2, n=6,0
    -4.3 ( 6.02 )
    99999 ( 99999 )
        CH50, Session 2, Day 3, predose, n=6,0
    -4.5 ( 6.16 )
    99999 ( 99999 )
        CH50, Session 2, Day 3, 2 hour, n=6,0
    -4.0 ( 5.55 )
    99999 ( 99999 )
        CH50, Session 2, Day 3, 4 hour, n=6,0
    -3.8 ( 6.31 )
    99999 ( 99999 )
        CH50, Session 2, Day 3, 8 hour, n=6,0
    -3.8 ( 3.92 )
    99999 ( 99999 )
        CH50, Session 2, Day 5, n=6,0
    -5.2 ( 6.31 )
    99999 ( 99999 )
        CH50, Session 2, Day 6, n=6,0
    -8.5 ( 9.61 )
    99999 ( 99999 )
        CH50, Session 3, Day 1, predose, n=6,0
    -4.5 ( 7.94 )
    99999 ( 99999 )
        CH50, Session 3, Day 1, 2 hour, n=6,0
    -4.2 ( 7.44 )
    99999 ( 99999 )
        CH50, Session 3, Day 1, 4 hour, n=6,0
    -4.5 ( 7.79 )
    99999 ( 99999 )
        CH50, Session 3, Day 1, 8 hour, n=6,0
    -4.8 ( 8.35 )
    99999 ( 99999 )
        CH50, Session 3, Day 2, n=5,0
    -3.6 ( 8.68 )
    99999 ( 99999 )
        CH50, Session 3, Day 3, predose, n=6,0
    -5.2 ( 8.86 )
    99999 ( 99999 )
        CH50, Session 3, Day 3, 2 hour, n=6,0
    -5.2 ( 8.86 )
    99999 ( 99999 )
        CH50, Session 3, Day 3, 4 hour, n=6,0
    -5.3 ( 8.57 )
    99999 ( 99999 )
        CH50, Session 3, Day 3, 8 hour, n=6,0
    -6.8 ( 10.05 )
    99999 ( 99999 )
        CH50, Session 3, Day 5, n=6,0
    -7.0 ( 10.28 )
    99999 ( 99999 )
        CH50, Session 3, Day 6, n=6,0
    -8.2 ( 11.02 )
    99999 ( 99999 )
        CH50, Session 4, Day 1, predose, n=5,0
    -3.0 ( 5.20 )
    99999 ( 99999 )
        CH50, Session 4, Day 1, 2 hour, n=5,0
    -2.0 ( 3.94 )
    99999 ( 99999 )
        CH50, Session 4, Day 1, 4 hour, n=5,0
    -1.6 ( 4.77 )
    99999 ( 99999 )
        CH50, Session 4, Day 1, 8 hour, n=5,0
    -1.6 ( 3.21 )
    99999 ( 99999 )
        CH50, Session 4, Day 2, n=5,0
    -1.6 ( 3.13 )
    99999 ( 99999 )
        CH50, Session 4, Day 3, predose, n=5,0
    -5.0 ( 6.08 )
    99999 ( 99999 )
        CH50, Session 4, Day 3, 2 hour, n=5,0
    -3.2 ( 4.09 )
    99999 ( 99999 )
        CH50, Session 4, Day 3, 4 hour, n=5,0
    -3.0 ( 6.40 )
    99999 ( 99999 )
        CH50, Session 4, Day 3, 8 hour, n=5,0
    -4.0 ( 6.04 )
    99999 ( 99999 )
        CH50, Session 4, Day 5, n=5,0
    -5.6 ( 7.70 )
    99999 ( 99999 )
        CH50, Session 4, Day 6, n=5,0
    -6.6 ( 7.83 )
    99999 ( 99999 )
        CH50, Session 5, Day 1, predose, n=4,0
    -3.8 ( 5.91 )
    99999 ( 99999 )
        CH50, Session 5, Day 1, 2 hour, n=4,0
    -3.0 ( 5.72 )
    99999 ( 99999 )
        CH50, Session 5, Day 1, 4 hour, n=4,0
    -2.8 ( 6.29 )
    99999 ( 99999 )
        CH50, Session 5, Day 1, 8 hour, n=4,0
    -3.0 ( 5.29 )
    99999 ( 99999 )
        CH50, Session 5, Day 2, n=4,0
    -3.5 ( 5.32 )
    99999 ( 99999 )
        CH50, Session 5, Day 3, predose, n=4,0
    -5.0 ( 5.77 )
    99999 ( 99999 )
        CH50, Session 5, Day 3, 2 hour, n=4,0
    -4.8 ( 6.80 )
    99999 ( 99999 )
        CH50, Session 5, Day 3, 4 hour, n=4,0
    -4.8 ( 6.70 )
    99999 ( 99999 )
        CH50, Session 5, Day 3, 8 hour, n=4,0
    -4.8 ( 6.80 )
    99999 ( 99999 )
        CH50, Session 5, Day 5, n=4,0
    -5.5 ( 7.72 )
    99999 ( 99999 )
        CH50, Session 5, Day 6, n=4,0
    -5.3 ( 8.54 )
    99999 ( 99999 )
        CH50, Session 6, Day 1, predose, n=4,0
    -2.3 ( 4.03 )
    99999 ( 99999 )
        CH50, Session 6, Day 1, 2 hour, n=4,0
    -2.8 ( 6.90 )
    99999 ( 99999 )
        CH50, Session 6, Day 1, 4 hour, n=4,0
    -3.3 ( 7.27 )
    99999 ( 99999 )
        CH50, Session 6, Day 1, 8 hour, n=4,0
    -3.5 ( 6.66 )
    99999 ( 99999 )
        CH50, Session 6, Day 2, n=4,0
    -4.3 ( 6.13 )
    99999 ( 99999 )
        CH50, Session 6, Day 3, predose, n=4,0
    -5.0 ( 8.52 )
    99999 ( 99999 )
        CH50, Session 6, Day 3, 2 hour, n=4,0
    -4.8 ( 8.54 )
    99999 ( 99999 )
        CH50, Session 6, Day 3, 4 hour, n=4,0
    -4.3 ( 8.66 )
    99999 ( 99999 )
        CH50, Session 6, Day 3, 8 hour, n=4,0
    -5.0 ( 8.52 )
    99999 ( 99999 )
        CH50, Session 6, Day 5, n=4,0
    -5.3 ( 9.00 )
    99999 ( 99999 )
        CH50, Session 6, Day 6, n=4,0
    -5.5 ( 9.47 )
    99999 ( 99999 )
    Notes
    [58] - Safety Population
    [59] - Safety Population
    No statistical analyses for this end point

    Secondary: Change from Baseline in inflammatory biomarkers over time

    Close Top of page
    End point title
    Change from Baseline in inflammatory biomarkers over time
    End point description
    Blood samples were collected for assessment of inflammatory biomarkers which included C-Reactive protein (CRP), high-sensitivity C-reactive protein (hsCRP), serum amyloid A protein (SAA). Baseline was considered as the latest assessment prior to first administration of either study drug, i.e. CPHPC or anti-SAP mAb. Change from Baseline was calculated as post-dose visit value minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. 88888 indicates data is not available, as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -1) and Session 1 to 6: Day 1 (predose, 2,4,8 hours), Day 2, Day 3 (predose, 2,4,8 hours), Day 5, Day 6
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [60]
    1 [61]
    Units: Milligrams per Liter (mg/L)
    arithmetic mean (standard deviation)
        CRP, Session 1, Day 1, predose, n=5,1
    -0.12 ( 0.572 )
    -4.60 ( 88888 )
        CRP, Session 1, Day 1, 2 hour, n=5,1
    -0.26 ( 0.573 )
    -4.80 ( 88888 )
        CRP, Session 1, Day 1, 4 hour, n=4,1
    -0.28 ( 0.486 )
    -4.70 ( 88888 )
        CRP, Session 1, Day 1, 8 hour, n=5,1
    -0.18 ( 0.634 )
    -4.60 ( 88888 )
        CRP, Session 1, Day 2, n=5,1
    0.64 ( 1.701 )
    44.70 ( 88888 )
        CRP, Session 1, Day 3, predose, n=5,1
    14.08 ( 12.511 )
    131.20 ( 88888 )
        CRP, Session 1, Day 3, 2 hour, n=5,0
    14.52 ( 13.128 )
    99999 ( 99999 )
        CRP, Session 1, Day 3, 4 hour, n=5,0
    15.30 ( 13.119 )
    99999 ( 99999 )
        CRP, Session 1, Day 3, 8 hour, n=5,0
    17.64 ( 14.527 )
    99999 ( 99999 )
        CRP, Session 1, Day 5, n=5,0
    17.20 ( 14.772 )
    99999 ( 99999 )
        CRP, Session 1, Day 6, n=5,0
    19.52 ( 15.665 )
    99999 ( 99999 )
        CRP, Session 2, Day 1, predose, n=5,0
    2.24 ( 2.864 )
    99999 ( 99999 )
        CRP, Session 2, Day 1, 2 hour, n=5,0
    2.12 ( 2.613 )
    99999 ( 99999 )
        CRP, Session 2, Day 1, 4 hour, n=5,0
    2.18 ( 2.710 )
    99999 ( 99999 )
        CRP, Session 2, Day 1, 8 hour, n=5,0
    2.18 ( 2.658 )
    99999 ( 99999 )
        CRP, Session 2, Day 2, n=4,0
    2.00 ( 2.624 )
    99999 ( 99999 )
        CRP, Session 2, Day 3, predose, n=5,0
    27.42 ( 26.283 )
    99999 ( 99999 )
        CRP, Session 2, Day 3, 2 hour, n=5,0
    29.46 ( 27.415 )
    99999 ( 99999 )
        CRP, Session 2, Day 3, 4 hour, n=5,0
    30.90 ( 27.961 )
    99999 ( 99999 )
        CRP, Session 2, Day 3, 8 hour, n=5,0
    31.76 ( 27.897 )
    99999 ( 99999 )
        CRP, Session 2, Day 5, n=4,0
    28.33 ( 22.386 )
    99999 ( 99999 )
        CRP, Session 2, Day 6, n=5,0
    27.04 ( 18.632 )
    99999 ( 99999 )
        CRP, Session 3, Day 1, predose, n=4,0
    1.93 ( 2.343 )
    99999 ( 99999 )
        CRP, Session 3, Day 1, 2 hour, n=4,0
    2.05 ( 2.626 )
    99999 ( 99999 )
        CRP, Session 3, Day 1, 4 hour, n=4,0
    2.15 ( 2.891 )
    99999 ( 99999 )
        CRP, Session 3, Day 1, 8 hour, n=4,0
    2.15 ( 2.760 )
    99999 ( 99999 )
        CRP, Session 3, Day 2, n=4,0
    1.75 ( 2.161 )
    99999 ( 99999 )
        CRP, Session 3, Day 3, predose, n=4,0
    18.13 ( 15.476 )
    99999 ( 99999 )
        CRP, Session 3, Day 3, 2 hour, n=4,0
    19.40 ( 16.403 )
    99999 ( 99999 )
        CRP, Session 3, Day 3, 4 hour, n=4,0
    21.20 ( 17.827 )
    99999 ( 99999 )
        CRP, Session 3, Day 3, 8 hour, n=4,0
    22.63 ( 18.466 )
    99999 ( 99999 )
        CRP, Session 3, Day 5, n=5,0
    19.00 ( 15.625 )
    99999 ( 99999 )
        CRP, Session 3, Day 6, n=4,0
    24.10 ( 16.785 )
    99999 ( 99999 )
        CRP, Session 4, Day 1, predose, n=4,0
    2.33 ( 4.487 )
    99999 ( 99999 )
        CRP, Session 4, Day 1, 2 hour, n=4,0
    2.53 ( 4.762 )
    99999 ( 99999 )
        CRP, Session 4, Day 1, 4 hour, n=4,0
    2.45 ( 4.669 )
    99999 ( 99999 )
        CRP, Session 4, Day 1, 8 hour, n=4,0
    2.40 ( 4.455 )
    99999 ( 99999 )
        CRP, Session 4, Day 2, n=4,0
    2.23 ( 3.963 )
    99999 ( 99999 )
        CRP, Session 4, Day 3, predose, n=4,0
    12.45 ( 13.533 )
    99999 ( 99999 )
        CRP, Session 4, Day 3, 2 hour, n=4,0
    14.75 ( 16.539 )
    99999 ( 99999 )
        CRP, Session 4, Day 3, 4 hour, n=4,0
    16.75 ( 19.129 )
    99999 ( 99999 )
        CRP, Session 4, Day 3, 8 hour, n=4,0
    17.30 ( 17.830 )
    99999 ( 99999 )
        CRP, Session 4, Day 5, n=4,0
    18.43 ( 9.959 )
    99999 ( 99999 )
        CRP, Session 4, Day 6, n=4,0
    19.98 ( 11.277 )
    99999 ( 99999 )
        CRP, Session 5, Day 1, predose, n=3,0
    2.23 ( 3.439 )
    99999 ( 99999 )
        CRP, Session 5, Day 1, 2 hour, n=3,0
    2.13 ( 3.350 )
    99999 ( 99999 )
        CRP, Session 5, Day 1, 4 hour, n=3,0
    1.97 ( 3.147 )
    99999 ( 99999 )
        CRP, Session 5, Day 1, 8 hour, n=3,0
    2.10 ( 3.378 )
    99999 ( 99999 )
        CRP, Session 5, Day 2, n=3,0
    1.37 ( 2.811 )
    99999 ( 99999 )
        CRP, Session 5, Day 3, predose, n=3,0
    8.33 ( 11.517 )
    99999 ( 99999 )
        CRP, Session 5, Day 3, 2 hour, n=3,0
    9.87 ( 12.881 )
    99999 ( 99999 )
        CRP, Session 5, Day 3, 4 hour, n=3,0
    10.47 ( 12.874 )
    99999 ( 99999 )
        CRP, Session 5, Day 3, 8 hour, n=3,0
    12.90 ( 14.944 )
    99999 ( 99999 )
        CRP, Session 5, Day 5, n=2,0
    34.30 ( 40.588 )
    99999 ( 99999 )
        CRP, Session 5, Day 6, n=2,0
    35.20 ( 34.931 )
    99999 ( 99999 )
        CRP, Session 6, Day 1, predose, n=3,0
    4.00 ( 3.851 )
    99999 ( 99999 )
        CRP, Session 6, Day 1, 2 hour, n=3,0
    3.63 ( 3.711 )
    99999 ( 99999 )
        CRP, Session 6, Day 1, 4 hour, n=3,0
    3.70 ( 3.835 )
    99999 ( 99999 )
        CRP, Session 6, Day 1, 8 hour, n=3,0
    3.70 ( 3.874 )
    99999 ( 99999 )
        CRP, Session 6, Day 2, n=3,0
    2.63 ( 2.914 )
    99999 ( 99999 )
        CRP, Session 6, Day 3, predose, n=3,0
    9.17 ( 8.879 )
    99999 ( 99999 )
        CRP, Session 6, Day 3, 2 hour, n=3,0
    11.10 ( 10.887 )
    99999 ( 99999 )
        CRP, Session 6, Day 3, 4 hour, n=3,0
    12.70 ( 11.555 )
    99999 ( 99999 )
        CRP, Session 6, Day 3, 8 hour, n=3,0
    14.67 ( 12.580 )
    99999 ( 99999 )
        CRP, Session 6, Day 5, n=3,0
    14.10 ( 7.146 )
    99999 ( 99999 )
        CRP, Session 6, Day 6, n=3,0
    17.33 ( 7.844 )
    99999 ( 99999 )
        hsCRP, Session 1, Day 1, predose, n=5,1
    -0.08 ( 0.356 )
    -3.60 ( 88888 )
        hsCRP, Session 1, Day 1, 2 hour, n=5,1
    -0.08 ( 0.327 )
    -3.70 ( 88888 )
        hsCRP, Session 1, Day 1, 4 hour, n=4,1
    -0.20 ( 0.271 )
    -3.70 ( 88888 )
        hsCRP, Session 1, Day 1, 8 hour, n=5,1
    -0.10 ( 0.406 )
    -3.60 ( 88888 )
        hsCRP, Session 1, Day 2, n=5,1
    0.56 ( 1.286 )
    41.40 ( 88888 )
        hsCRP, Session 1, Day 3, predose, n=5,1
    14.54 ( 13.149 )
    135.20 ( 88888 )
        hsCRP, Session 1, Day 3, 2 hour, n=5,0
    15.14 ( 13.363 )
    99999 ( 99999 )
        hsCRP, Session 1, Day 3, 4 hour, n=5,0
    15.84 ( 13.607 )
    99999 ( 99999 )
        hsCRP, Session 1, Day 3, 8 hour, n=5,0
    17.10 ( 14.294 )
    99999 ( 99999 )
        hsCRP, Session 1, Day 5, n=5,0
    16.70 ( 14.332 )
    99999 ( 99999 )
        hsCRP, Session 1, Day 6, n=5,0
    18.60 ( 14.778 )
    99999 ( 99999 )
        hsCRP, Session 2, Day 1, predose, n=5,0
    1.88 ( 2.539 )
    99999 ( 99999 )
        hsCRP, Session 2, Day 1, 2 hour, n=5,0
    1.78 ( 2.351 )
    99999 ( 99999 )
        hsCRP, Session 2, Day 1, 4 hour, n=5,0
    1.90 ( 2.478 )
    99999 ( 99999 )
        hsCRP, Session 2, Day 1, 8 hour, n=5,0
    1.78 ( 2.179 )
    99999 ( 99999 )
        hsCRP, Session 2, Day 2, n=4,0
    1.75 ( 2.266 )
    99999 ( 99999 )
        hsCRP, Session 2, Day 3, predose, n=5,0
    26.76 ( 26.122 )
    99999 ( 99999 )
        hsCRP, Session 2, Day 3, 2 hour, n=5,0
    29.28 ( 27.373 )
    99999 ( 99999 )
        hsCRP, Session 2, Day 3, 4 hour, n=5,0
    30.36 ( 27.018 )
    99999 ( 99999 )
        hsCRP, Session 2, Day 3, 8 hour, n=5,0
    31.10 ( 26.885 )
    99999 ( 99999 )
        hsCRP, Session 2, Day 5, n=4,0
    28.13 ( 21.919 )
    99999 ( 99999 )
        hsCRP, Session 2, Day 6, n=5,0
    27.20 ( 18.468 )
    99999 ( 99999 )
        hsCRP, Session 3, Day 1, predose, n=4,0
    1.60 ( 2.017 )
    99999 ( 99999 )
        hsCRP, Session 3, Day 1, 2 hour, n=4,0
    1.63 ( 2.175 )
    99999 ( 99999 )
        hsCRP, Session 3, Day 1, 4 hour, n=4,0
    1.70 ( 2.403 )
    99999 ( 99999 )
        hsCRP, Session 3, Day 1, 8 hour, n=4,0
    1.65 ( 2.161 )
    99999 ( 99999 )
        hsCRP, Session 3, Day 2, n=4,0
    1.25 ( 1.754 )
    99999 ( 99999 )
        hsCRP, Session 3, Day 3, predose, n=4,0
    17.88 ( 15.954 )
    99999 ( 99999 )
        hsCRP, Session 3, Day 3, 2 hour, n=4,0
    19.23 ( 16.675 )
    99999 ( 99999 )
        hsCRP, Session 3, Day 3, 4 hour, n=4,0
    20.58 ( 17.733 )
    99999 ( 99999 )
        hsCRP, Session 3, Day 3, 8 hour, n=4,0
    22.10 ( 18.149 )
    99999 ( 99999 )
        hsCRP, Session 3, Day 5, n=4,0
    22.45 ( 15.042 )
    99999 ( 99999 )
        hsCRP, Session 3, Day 6, n=4,0
    23.73 ( 16.141 )
    99999 ( 99999 )
        hsCRP, Session 4, Day 1, predose, n=4,0
    2.28 ( 4.043 )
    99999 ( 99999 )
        hsCRP, Session 4, Day 1, 2 hour, n=4,0
    2.53 ( 4.610 )
    99999 ( 99999 )
        hsCRP, Session 4, Day 1, 4 hour, n=4,0
    2.53 ( 4.479 )
    99999 ( 99999 )
        hsCRP, Session 4, Day 1, 8 hour, n=4,0
    2.58 ( 4.528 )
    99999 ( 99999 )
        hsCRP, Session 4, Day 2, n=4,0
    2.20 ( 3.558 )
    99999 ( 99999 )
        hsCRP, Session 4, Day 3, predose, n=4,0
    12.33 ( 13.881 )
    99999 ( 99999 )
        hsCRP, Session 4, Day 3, 2 hour, n=4,0
    14.40 ( 16.324 )
    99999 ( 99999 )
        hsCRP, Session 4, Day 3, 4 hour, n=4,0
    16.00 ( 18.240 )
    99999 ( 99999 )
        hsCRP, Session 4, Day 3, 8 hour, n=4,0
    17.08 ( 17.972 )
    99999 ( 99999 )
        hsCRP, Session 4, Day 5, n=4,0
    19.60 ( 10.903 )
    99999 ( 99999 )
        hsCRP, Session 4, Day 6, n=4,0
    20.73 ( 11.391 )
    99999 ( 99999 )
        hsCRP, Session 5, Day 1, predose, n=3,0
    2.03 ( 3.349 )
    99999 ( 99999 )
        hsCRP, Session 5, Day 1, 2 hour, n=3,0
    1.97 ( 3.320 )
    99999 ( 99999 )
        hsCRP, Session 5, Day 1, 4 hour, n=3,0
    1.83 ( 3.175 )
    99999 ( 99999 )
        hsCRP, Session 5, Day 1, 8 hour, n=3,0
    1.87 ( 3.323 )
    99999 ( 99999 )
        hsCRP, Session 5, Day 2, n=3,0
    1.23 ( 2.574 )
    99999 ( 99999 )
        hsCRP, Session 5, Day 3, predose, n=3,0
    9.10 ( 13.182 )
    99999 ( 99999 )
        hsCRP, Session 5, Day 3, 2 hour, n=3,0
    10.43 ( 14.629 )
    99999 ( 99999 )
        hsCRP, Session 5, Day 3, 4 hour, n=3,0
    11.17 ( 14.865 )
    99999 ( 99999 )
        hsCRP, Session 5, Day 3, 8 hour, n=3,0
    12.67 ( 15.557 )
    99999 ( 99999 )
        hsCRP, Session 5, Day 5, n=2,0
    33.95 ( 40.941 )
    99999 ( 99999 )
        hsCRP, Session 5, Day 6, n=2,0
    34.80 ( 34.083 )
    99999 ( 99999 )
        hsCRP, Session 6, Day 1, predose, n=3,0
    3.77 ( 3.853 )
    99999 ( 99999 )
        hsCRP, Session 6, Day 1, 2 hour, n=3,0
    3.37 ( 3.523 )
    99999 ( 99999 )
        hsCRP, Session 6, Day 1, 4 hour, n=3,0
    3.50 ( 3.799 )
    99999 ( 99999 )
        hsCRP, Session 6, Day 1, 8 hour, n=3,0
    3.27 ( 3.584 )
    99999 ( 99999 )
        hsCRP, Session 6, Day 2, n=3,0
    2.33 ( 2.775 )
    99999 ( 99999 )
        hsCRP, Session 6, Day 3, predose, n=3,0
    8.97 ( 9.752 )
    99999 ( 99999 )
        hsCRP, Session 6, Day 3, 2 hour, n=3,0
    10.57 ( 11.075 )
    99999 ( 99999 )
        hsCRP, Session 6, Day 3, 4 hour, n=3,0
    12.60 ( 12.322 )
    99999 ( 99999 )
        hsCRP, Session 6, Day 3, 8 hour, n=3,0
    15.33 ( 14.276 )
    99999 ( 99999 )
        hsCRP, Session 6, Day 5, n=3,0
    14.43 ( 7.801 )
    99999 ( 99999 )
        hsCRP, Session 6, Day 6, n=3,0
    18.63 ( 8.607 )
    99999 ( 99999 )
        SAA, Session 1, Day 1, predose, n=5,1
    0.2164 ( 1.55486 )
    -22.3723 ( 88888 )
        SAA, Session 1, Day 1, 2 hour, n=5,1
    0.1738 ( 1.13909 )
    -22.4187 ( 88888 )
        SAA, Session 1, Day 1, 4 hour, n=5,1
    0.3902 ( 1.56253 )
    -21.7463 ( 88888 )
        SAA, Session 1, Day 1, 8 hour, n=5,1
    0.2695 ( 1.57992 )
    -14.8767 ( 88888 )
        SAA, Session 1, Day 2, n=5,1
    2.9247 ( 3.47577 )
    322.2895 ( 88888 )
        SAA, Session 1, Day 3, predose, n=5,1
    50.7137 ( 55.02969 )
    1437.7667 ( 88888 )
        SAA, Session 1, Day 3, 2 hour, n=5,0
    54.8466 ( 59.36005 )
    99999 ( 99999 )
        SAA, Session 1, Day 3, 4 hour, n=5,0
    54.9329 ( 55.92645 )
    99999 ( 99999 )
        SAA, Session 1, Day 3, 8 hour, n=5,0
    68.4699 ( 75.51138 )
    99999 ( 99999 )
        SAA, Session 1, Day 5, n=5,0
    54.6741 ( 69.66316 )
    99999 ( 99999 )
        SAA, Session 1, Day 6, n=5,0
    55.2882 ( 63.77870 )
    99999 ( 99999 )
        SAA, Session 2, Day 1, predose, n=5,0
    1.0277 ( 1.64965 )
    99999 ( 99999 )
        SAA, Session 2, Day 1, 2 hour, n=5,0
    0.9841 ( 2.22042 )
    99999 ( 99999 )
        SAA, Session 2, Day 1, 4 hour, n=5,0
    1.4543 ( 2.61184 )
    99999 ( 99999 )
        SAA, Session 2, Day 1, 8 hour, n=5,0
    1.0588 ( 1.52455 )
    99999 ( 99999 )
        SAA, Session 2, Day 2, n=5,0
    3.7244 ( 1.63856 )
    99999 ( 99999 )
        SAA, Session 2, Day 3, predose, n=5,0
    134.4489 ( 160.14208 )
    99999 ( 99999 )
        SAA, Session 2, Day 3, 2 hour, n=5,0
    145.2507 ( 171.92591 )
    99999 ( 99999 )
        SAA, Session 2, Day 3, 4 hour, n=5,0
    142.5438 ( 174.11156 )
    99999 ( 99999 )
        SAA, Session 2, Day 3, 8 hour, n=5,0
    100.8836 ( 184.35963 )
    99999 ( 99999 )
        SAA, Session 2, Day 5, n=5,0
    76.8593 ( 136.83379 )
    99999 ( 99999 )
        SAA, Session 2, Day 6, n=5,0
    101.0688 ( 105.88787 )
    99999 ( 99999 )
        SAA, Session 3, Day 1, predose, n=4,0
    0.2428 ( 1.13002 )
    99999 ( 99999 )
        SAA, Session 3, Day 1, 2 hour, n=4,0
    0.1863 ( 1.06333 )
    99999 ( 99999 )
        SAA, Session 3, Day 1, 4 hour, n=4,0
    0.0475 ( 1.00422 )
    99999 ( 99999 )
        SAA, Session 3, Day 1, 8 hour, n=5,0
    4.0339 ( 8.62955 )
    99999 ( 99999 )
        SAA, Session 3, Day 2, n=4,0
    6.4822 ( 11.14119 )
    99999 ( 99999 )
        SAA, Session 3, Day 3, predose, n=5,0
    54.7393 ( 82.22346 )
    99999 ( 99999 )
        SAA, Session 3, Day 3, 2 hour, n=5,0
    58.0526 ( 83.12677 )
    99999 ( 99999 )
        SAA, Session 3, Day 3, 4 hour, n=5,0
    64.1995 ( 93.61736 )
    99999 ( 99999 )
        SAA, Session 3, Day 3, 8 hour, n=5,0
    66.9605 ( 93.98658 )
    99999 ( 99999 )
        SAA, Session 3, Day 5, n=5,0
    58.6742 ( 50.93398 )
    99999 ( 99999 )
        SAA, Session 3, Day 6, n=5,0
    49.4029 ( 46.30012 )
    99999 ( 99999 )
        SAA, Session 4, Day 1, predose, n=4,0
    -0.1305 ( 1.86822 )
    99999 ( 99999 )
        SAA, Session 4, Day 1, 2 hour, n=4,0
    0.0159 ( 1.91086 )
    99999 ( 99999 )
        SAA, Session 4, Day 1, 4 hour, n=4,0
    -0.0013 ( 1.84104 )
    99999 ( 99999 )
        SAA, Session 4, Day 1, 8 hour, n=4,0
    0.1997 ( 1.70496 )
    99999 ( 99999 )
        SAA, Session 4, Day 2, n=4,0
    1.6015 ( 1.07082 )
    99999 ( 99999 )
        SAA, Session 4, Day 3, predose, n=4,0
    45.1067 ( 82.67535 )
    99999 ( 99999 )
        SAA, Session 4, Day 3, 2 hour, n=4,0
    51.0650 ( 94.33211 )
    99999 ( 99999 )
        SAA, Session 4, Day 3, 4 hour, n=4,0
    55.0009 ( 101.37965 )
    99999 ( 99999 )
        SAA, Session 4, Day 3, 8 hour, n=4,0
    55.7135 ( 101.39069 )
    99999 ( 99999 )
        SAA, Session 4, Day 5, n=4,0
    51.2002 ( 54.84780 )
    99999 ( 99999 )
        SAA, Session 4, Day 6, n=4,0
    41.2457 ( 38.77052 )
    99999 ( 99999 )
        SAA, Session 5, Day 1, predose, n=3,0
    -0.1498 ( 1.04561 )
    99999 ( 99999 )
        SAA, Session 5, Day 1, 2 hour, n=3,0
    -0.2399 ( 0.89843 )
    99999 ( 99999 )
        SAA, Session 5, Day 1, 4 hour, n=3,0
    -0.1906 ( 0.94124 )
    99999 ( 99999 )
        SAA, Session 5, Day 1, 8 hour, n=3,0
    -0.1771 ( 0.95814 )
    99999 ( 99999 )
        SAA, Session 5, Day 2, n=3,0
    0.1380 ( 0.61958 )
    99999 ( 99999 )
        SAA, Session 5, Day 3, predose, n=3,0
    10.8884 ( 17.72052 )
    99999 ( 99999 )
        SAA, Session 5, Day 3, 2 hour, n=3,0
    8.6783 ( 11.48176 )
    99999 ( 99999 )
        SAA, Session 5, Day 3, 4 hour, n=3,0
    9.2527 ( 11.23663 )
    99999 ( 99999 )
        SAA, Session 5, Day 3, 8 hour, n=3,0
    13.7941 ( 19.39827 )
    99999 ( 99999 )
        SAA, Session 5, Day 5, n=3,0
    66.2542 ( 107.98594 )
    99999 ( 99999 )
        SAA, Session 5, Day 6, n=3,0
    73.0823 ( 118.07036 )
    99999 ( 99999 )
        SAA, Session 6, Day 1, predose, n=3,0
    1.2964 ( 1.75482 )
    99999 ( 99999 )
        SAA, Session 6, Day 1, 2 hour, n=3,0
    1.0538 ( 1.74392 )
    99999 ( 99999 )
        SAA, Session 6, Day 1, 4 hour, n=3,0
    1.3139 ( 2.18542 )
    99999 ( 99999 )
        SAA, Session 6, Day 1, 8 hour, n=3,0
    0.9078 ( 1.72500 )
    99999 ( 99999 )
        SAA, Session 6, Day 2, n=3,0
    1.2641 ( 0.89837 )
    99999 ( 99999 )
        SAA, Session 6, Day 3, predose, n=3,0
    7.4697 ( 5.41886 )
    99999 ( 99999 )
        SAA, Session 6, Day 3, 2 hour, n=3,0
    8.3574 ( 4.40865 )
    99999 ( 99999 )
        SAA, Session 6, Day 3, 4 hour, n=3,0
    11.0305 ( 8.80978 )
    99999 ( 99999 )
        SAA, Session 6, Day 3, 8 hour, n=3,0
    14.5333 ( 12.26460 )
    99999 ( 99999 )
        SAA, Session 6, Day 5, n=3,0
    25.2529 ( 27.55204 )
    99999 ( 99999 )
        SAA, Session 6, Day 6, n=3,0
    32.6318 ( 41.82856 )
    99999 ( 99999 )
    Notes
    [60] - Safety Population
    [61] - Safety Population
    No statistical analyses for this end point

    Secondary: Maximum concentration (Cmax) of GSK2398852

    Close Top of page
    End point title
    Maximum concentration (Cmax) of GSK2398852
    End point description
    Blood samples were collected for evaluation of Pharmacokinetic (PK) parameters including Cmax at indicated time points. Geometric mean and geometric coefficient of variation of Cmax is presented. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. 88888 indicates data is not available, as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Session 1 to 6: Day 1 (Pre-dose, 6, 8, 12 hour), Day 2, Day 3 (Pre-dose and at 6 hour), Day 4, Day 7 and Day 11
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [62]
    1 [63]
    Units: Micrograms per milliliter (ug/mL)
    geometric mean (geometric coefficient of variation)
        Session 1, n=6,1
    86.94 ( 31.58 )
    88.64 ( 88888 )
        Session 2, n=6,0
    235.48 ( 25.22 )
    99999 ( 99999 )
        Session 3, n=6,0
    222.23 ( 44.40 )
    99999 ( 99999 )
        Session 4, n=5,0
    179.82 ( 33.87 )
    99999 ( 99999 )
        Session 5, n=4,0
    185.52 ( 34.06 )
    99999 ( 99999 )
        Session 6, n=4,0
    228.51 ( 49.73 )
    99999 ( 99999 )
    Notes
    [62] - Safety Population
    [63] - Safety Population
    No statistical analyses for this end point

    Secondary: Time associated with Cmax (Tmax) of GSK2398852

    Close Top of page
    End point title
    Time associated with Cmax (Tmax) of GSK2398852
    End point description
    Blood samples were collected for evaluation of PK parameters including Tmax at indicated time points. Median and full range of Tmax is presented. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available.
    End point type
    Secondary
    End point timeframe
    Session 1 to 6: Day 1 (Pre-dose, 6, 8, 12 hour), Day 2, Day 3 (Pre-dose and at 6 hour), Day 4, Day 7 and Day 11
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [64]
    1 [65]
    Units: Hour
    median (full range (min-max))
        Session 1, n=6,1
    54.18 (53.9 to 54.9)
    6.1 (6.1 to 6.1)
        Session 2, n=6,0
    54.07 (53.3 to 54.7)
    99999 (-99999 to 99999)
        Session 3, n=6,0
    54.06 (12.1 to 55.8)
    99999 (-99999 to 99999)
        Session 4, n=5,0
    54.50 (53.9 to 56.1)
    99999 (-99999 to 99999)
        Session 5, n=4,0
    54.28 (6.1 to 56.1)
    99999 (-99999 to 99999)
        Session 6, n=4,0
    54.18 (53.9 to 56.0)
    99999 (-99999 to 99999)
    Notes
    [64] - Safety Population
    [65] - Safety Population
    No statistical analyses for this end point

    Secondary: Area under the plasma concentration-time curve from time zero to time t (AUC 0-t) of GSK2398852

    Close Top of page
    End point title
    Area under the plasma concentration-time curve from time zero to time t (AUC 0-t) of GSK2398852
    End point description
    Blood samples were collected for evaluation of PK parameters including AUC 0-t at indicated time points. Geometric mean and geometric coefficient of variation of AUC0-t is presented. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. 88888 indicates data is not available, as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Session 1 to 6: Day 1 (Pre-dose, 6, 8, 12 hour), Day 2, Day 3 (Pre-dose and at 6 hour), Day 4, Day 7 and Day 11
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [66]
    1 [67]
    Units: Hour*micrograms per milliliter (h*ug/mL)
    geometric mean (geometric coefficient of variation)
        Session 1, n=6,1
    5130.0 ( 46.72 )
    2148.2 ( 88888 )
        Session 2, n=6,0
    14610.1 ( 34.73 )
    99999 ( 99999 )
        Session 3, n=6,0
    13804.6 ( 50.34 )
    99999 ( 99999 )
        Session 4, n=5,0
    12970.9 ( 51.52 )
    99999 ( 99999 )
        Session 5, n=4,0
    15595.3 ( 51.13 )
    99999 ( 99999 )
        Session 6, n=4,0
    17126.7 ( 43.98 )
    99999 ( 99999 )
    Notes
    [66] - Safety Population
    [67] - Safety Population
    No statistical analyses for this end point

    Secondary: Cmax of GSK2315698 for newly diagnosed Mayo stage II/IIIa AL Amyloidosis participants

    Close Top of page
    End point title
    Cmax of GSK2315698 for newly diagnosed Mayo stage II/IIIa AL Amyloidosis participants
    End point description
    Blood samples were planned to be collected for evaluation of PK parameters including Cmax at indicated time points for GSK2315698 for newly diagnosed Mayo stage II/IIIa AL Amyloidosis participants. However, no participant was enrolled in 'Group 3: Newly diagnosed Mayo stage II/IIIa AL participants.' Safety Population. Data was not collected for this outcome due to blood samples were not collected to evaluate PK of GSK2315698 as no participant was enrolled in 'Group 3: Newly diagnosed Mayo stage II/IIIa AL participants'.
    End point type
    Secondary
    End point timeframe
    Day 1: Pre-dose; Day 2 (pre-dose and 2 hours post-dose); Day 3: Pre-dose in each session (each session of 24 days)
    End point values
    Number of subjects analysed
    Units: ug/mL
        geometric mean (geometric coefficient of variation)
    No statistical analyses for this end point

    Secondary: Tmax of GSK2315698 for newly diagnosed Mayo stage II/IIIa AL Amyloidosis participants

    Close Top of page
    End point title
    Tmax of GSK2315698 for newly diagnosed Mayo stage II/IIIa AL Amyloidosis participants
    End point description
    Blood samples were planned to be collected for evaluation of PK parameters including Tmax at indicated time points for GSK2315698 for newly diagnosed Mayo stage II/IIIa AL Amyloidosis participants. However, no participant was enrolled in 'Group 3: Newly diagnosed Mayo stage II/IIIa AL participants'. Data was not collected for this outcome due to blood samples were not collected to evaluate PK of GSK2315698 as no participant was enrolled in 'Group 3: Newly diagnosed Mayo stage II/IIIa AL participants'.
    End point type
    Secondary
    End point timeframe
    Day 1: Pre-dose; Day 2: pre-dose and 2 hours post-dose; Day 3: Pre-dose in each session (each session of 24 days)
    End point values
    Number of subjects analysed
    Units: Hour
        median (full range (min-max))
    No statistical analyses for this end point

    Secondary: AUC 0-t of GSK2315698 for newly diagnosed Mayo stage II/IIIa AL Amyloidosis participants

    Close Top of page
    End point title
    AUC 0-t of GSK2315698 for newly diagnosed Mayo stage II/IIIa AL Amyloidosis participants
    End point description
    Blood samples were planned to be collected for evaluation of PK parameters including AUC0-t at indicated time points for GSK2315698 for newly diagnosed Mayo stage II/IIIa AL Amyloidosis participants. However, no participant was enrolled in 'Group 3: Newly diagnosed Mayo stage II/IIIa AL participants'. Safety Population. Data was not collected for this outcome due to blood samples were not collected to evaluate PK of GSK2315698 as no participant was enrolled in 'Group 3: Newly diagnosed Mayo stage II/IIIa AL participants'.
    End point type
    Secondary
    End point timeframe
    Day 1: Pre-dose; Day 2 (pre-dose and 2 hours post-dose); Day 3: Pre-dose in each session (each session of 24 days)
    End point values
    Number of subjects analysed
    Units: Hour*ug/mL
        geometric mean (geometric coefficient of variation)
    No statistical analyses for this end point

    Secondary: Change from Baseline in Global Longitudinal Strain (GLS) by CMR

    Close Top of page
    End point title
    Change from Baseline in Global Longitudinal Strain (GLS) by CMR
    End point description
    Global Longitudinal Strain was measured by CMR at indicated time points. GLS included feature tracking and tagging by CMR. Baseline was considered as the latest assessment prior to first administration of either study drug, i.e. CPHPC or anti-SAP mAb. Change from Baseline was calculated as post-dose visit value minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. 88888 indicates data is not available, as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -1) and Session 2 to 5: Day 24; 8 week follow-up; 6 months follow-up
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [68]
    1 [69]
    Units: Percentage of myocardial shortening
    arithmetic mean (standard deviation)
        GLS Tagging, Session 2, Day 24, n=6,0
    0.003 ( 0.2907 )
    99999 ( 99999 )
        GLS Tagging, Session 3, Day 24, n=6,0
    0.229 ( 0.5836 )
    99999 ( 99999 )
        GLS Tagging, Session 4, Day 24, n=5,0
    0.392 ( 0.4121 )
    99999 ( 99999 )
        GLS Tagging, Session 5, Day 24, n=4,0
    0.349 ( 0.9354 )
    99999 ( 99999 )
        GLS Tagging, 8 Week follow-up, n=6,1
    1.125 ( 1.6448 )
    -3.404 ( 88888 )
        GLS Tagging, 6 month follow-up, n=2,0
    -1.014 ( 0.3654 )
    99999 ( 99999 )
        GLS Feature Tracking, Session 2, Day 24, n=6,0
    1.729 ( 2.3613 )
    99999 ( 99999 )
        GLS Feature Tracking, Session 3, Day 24, n=6,0
    0.803 ( 2.3712 )
    99999 ( 99999 )
        GLS Feature Tracking, Session 4, Day 24, n=5,0
    1.326 ( 4.0639 )
    99999 ( 99999 )
        GLS Feature Tracking, Session 5, Day 24, n=4,0
    1.657 ( 2.1277 )
    99999 ( 99999 )
        GLS Feature Tracking, 8 Week follow-up, n=6,1
    0.639 ( 1.3678 )
    3.951 ( 88888 )
        GLS Feature Tracking, 6 month follow-up, n=2,0
    1.234 ( 4.6888 )
    99999 ( 99999 )
    Notes
    [68] - Safety Population
    [69] - Safety Population
    No statistical analyses for this end point

    Secondary: Change from Baseline in GLS by ECHO

    Close Top of page
    End point title
    Change from Baseline in GLS by ECHO
    End point description
    Global Longitudinal Strain was measured by ECHO at indicated time points. GLS included speckle tracking by ECHO. Baseline was considered as the latest assessment prior to first administration of either study drug, i.e. CPHPC or anti-SAP mAb. Change from Baseline was calculated as post-dose visit value minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. 88888 indicates data is not available, as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -1) and Session 1 to 6: Day 24; 8 week follow-up; 6 months follow-up
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [70]
    1 [71]
    Units: Percentage of myocardial shortening
    arithmetic mean (standard deviation)
        GLS Speckle Tracking, Session 1, Day 24, n=6,1
    -3.55 ( 5.709 )
    -0.90 ( 88888 )
        GLS Speckle Tracking, Session 2, Day 24, n=6,0
    -0.58 ( 6.013 )
    99999 ( 99999 )
        GLS Speckle Tracking, Session 3, Day 24, n=6,0
    -1.17 ( 7.487 )
    99999 ( 99999 )
        GLS Speckle Tracking, Session 4, Day 24, n=5,0
    1.26 ( 5.299 )
    99999 ( 99999 )
        GLS Speckle Tracking, Session 5, Day 24, n=4,0
    1.13 ( 9.044 )
    99999 ( 99999 )
        GLS Speckle Tracking, Session 6, Day 24, n=4,0
    -2.08 ( 4.555 )
    99999 ( 99999 )
        GLS Speckle Tracking, 8 Week follow-up, n=6,1
    -1.82 ( 10.013 )
    1.60 ( 88888 )
        GLS Speckle Tracking, 6 month follow-up, n=4,0
    0.40 ( 4.268 )
    99999 ( 99999 )
    Notes
    [70] - Safety Population
    [71] - Safety Population
    No statistical analyses for this end point

    Secondary: Change from Baseline in LV twist over time

    Close Top of page
    End point title
    Change from Baseline in LV twist over time
    End point description
    LV twist was measured by CMR at indicated time points. Baseline was considered as the latest assessment prior to first administration of either study drug, i.e. CPHPC or anti-SAP mAb. Change from Baseline was calculated as post-dose visit value minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. 88888 indicates data is not available, as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -1) and Session 2 to 5: Day 24; 8 week follow-up; 6 months follow-up
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [72]
    1 [73]
    Units: Degree
    arithmetic mean (standard deviation)
        Session 2, Day 24, n=5,0
    0.550 ( 1.6672 )
    99999 ( 99999 )
        Session 3, Day 24, n=6,0
    0.431 ( 2.4369 )
    99999 ( 99999 )
        Session 4, Day 24, n=5,0
    -0.611 ( 1.8979 )
    99999 ( 99999 )
        Session 5, Day 24, n=4,0
    -0.628 ( 1.2269 )
    99999 ( 99999 )
        8 Week follow-up, n=6,1
    -0.264 ( 2.0835 )
    0.914 ( 88888 )
        6 month follow-up, n=2,0
    -0.633 ( 0.3349 )
    99999 ( 99999 )
    Notes
    [72] - Safety Population
    [73] - Safety Population
    No statistical analyses for this end point

    Secondary: Change from Baseline in Stroke Volume (SV) by CMR

    Close Top of page
    End point title
    Change from Baseline in Stroke Volume (SV) by CMR
    End point description
    Stroke volume is the amount of blood ejected by the left ventricle in one contraction. SV was measured by CMR at indicated time points. Baseline was considered as the latest assessment prior to first administration of either study drug, i.e. CPHPC or anti-SAP mAb. Change from Baseline was calculated as post-dose visit value minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. 88888 indicates data is not available, as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -1) and Session 2 to 5: Day 24; 8 week follow-up; 6 months follow-up
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [74]
    1 [75]
    Units: Milliliter
    arithmetic mean (standard deviation)
        Session 2, Day 24, n=6,0
    -2.760 ( 7.8305 )
    99999 ( 99999 )
        Session 3, Day 24, n=6,0
    -1.228 ( 24.3834 )
    99999 ( 99999 )
        Session 4, Day 24, n=5,0
    -9.766 ( 9.7838 )
    99999 ( 99999 )
        Session 5, Day 24, n=4,0
    -11.477 ( 14.4238 )
    99999 ( 99999 )
        8 Week follow-up, n=6,1
    2.400 ( 19.1252 )
    -6.750 ( 88888 )
        6 month follow-up, n=2,0
    -6.160 ( 12.0491 )
    99999 ( 99999 )
    Notes
    [74] - Safety Population
    [75] - Safety Population
    No statistical analyses for this end point

    Secondary: Change from Baseline in SV by ECHO

    Close Top of page
    End point title
    Change from Baseline in SV by ECHO
    End point description
    Stroke volume is the amount of blood ejected by the left ventricle in one contraction. SV was measured by ECHO at indicated time points. Baseline was considered as the latest assessment prior to first administration of either study drug, i.e. CPHPC or anti-SAP mAb. Change from Baseline was calculated as post-dose visit value minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. 88888 indicates data is not available, as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -1) and Session 1 to 6: Day 24; 8 week follow-up; 6 months follow-up
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [76]
    1 [77]
    Units: Milliliter
    arithmetic mean (standard deviation)
        Session 1, Day 24, n=6,1
    2.580 ( 5.4518 )
    -5.640 ( 88888 )
        Session 2, Day 24, n=6,0
    -1.885 ( 4.6569 )
    99999 ( 99999 )
        Session 3, Day 24, n=6,0
    -1.398 ( 8.0106 )
    99999 ( 99999 )
        Session 4, Day 24, n=5,0
    -7.484 ( 6.5228 )
    99999 ( 99999 )
        Session 5, Day 24, n=4,0
    -9.043 ( 9.5173 )
    99999 ( 99999 )
        Session 6, Day 24, n=4,0
    -5.095 ( 7.1431 )
    99999 ( 99999 )
        8 Week follow-up, n=6,1
    -4.343 ( 7.3457 )
    -6.490 ( 88888 )
        6 month follow-up, n=4,0
    -4.275 ( 9.9743 )
    99999 ( 99999 )
    Notes
    [76] - Safety Population
    [77] - Safety Population
    No statistical analyses for this end point

    Secondary: Change from Baseline in left ventricular ejection fraction (EF) by CMR

    Close Top of page
    End point title
    Change from Baseline in left ventricular ejection fraction (EF) by CMR
    End point description
    Left ventricular ejection fraction is a measurement of the percentage of blood leaving the heart each time it contracts. EF was measured by CMR at indicated time points. Baseline was considered as the latest assessment prior to first administration of either study drug, i.e. CPHPC or anti-SAP mAb. Change from Baseline was calculated as post-dose visit value minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. 88888 indicates data is not available, as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -1) and Session 2 to 5: Day 24; 8 week follow-up; 6 months follow-up
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [78]
    1 [79]
    Units: Percentage of ejected blood
    arithmetic mean (standard deviation)
        Session 2, Day 24, n=6,0
    0.100 ( 3.9071 )
    99999 ( 99999 )
        Session 3, Day 24, n=6,0
    0.687 ( 11.7171 )
    99999 ( 99999 )
        Session 4, Day 24, n=5,0
    -3.380 ( 5.4750 )
    99999 ( 99999 )
        Session 5, Day 24, n=4,0
    -3.257 ( 7.9513 )
    99999 ( 99999 )
        8 Week follow-up, n=6,1
    -1.258 ( 7.9932 )
    -2.800 ( 88888 )
        6 month follow-up, n=2,0
    0.680 ( 8.7681 )
    99999 ( 99999 )
    Notes
    [78] - Safety Population
    [79] - Safety Population
    No statistical analyses for this end point

    Secondary: Change from Baseline in left ventricular EF by ECHO

    Close Top of page
    End point title
    Change from Baseline in left ventricular EF by ECHO
    End point description
    Left ventricular ejection fraction is a measurement of the percentage of blood leaving the heart each time it contracts. EF was measured by ECHO at indicated time points. Baseline was considered as the latest assessment prior to first administration of either study drug, i.e. CPHPC or anti-SAP mAb. Change from Baseline was calculated as post-dose visit value minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. 88888 indicates data is not available, as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -1) and Session 1 to 6: Day 24; 8 week follow-up; 6 months follow-up
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [80]
    1 [81]
    Units: Percentage of ejected blood
    arithmetic mean (standard deviation)
        Session 1, Day 24, n=6,1
    2.10 ( 5.707 )
    -7.40 ( 88888 )
        Session 2, Day 24, n=6,0
    -0.38 ( 3.111 )
    99999 ( 99999 )
        Session 3, Day 24, n=6,0
    -0.30 ( 3.318 )
    99999 ( 99999 )
        Session 4, Day 24, n=5,0
    -2.74 ( 5.766 )
    99999 ( 99999 )
        Session 5, Day 24, n=4,0
    -4.05 ( 7.832 )
    99999 ( 99999 )
        Session 6, Day 24, n=4,0
    -3.53 ( 3.288 )
    99999 ( 99999 )
        8 Week follow-up, n=6,1
    -1.72 ( 8.471 )
    -3.20 ( 88888 )
        6 month follow-up, n=4,0
    1.20 ( 3.442 )
    99999 ( 99999 )
    Notes
    [80] - Safety Population
    [81] - Safety Population
    No statistical analyses for this end point

    Secondary: Change from Baseline in left ventricle End Diastolic Volume (EDV) by CMR

    Close Top of page
    End point title
    Change from Baseline in left ventricle End Diastolic Volume (EDV) by CMR
    End point description
    Left ventricle EDV is the volume of blood in the left ventricle at end load or filling in (diastole) or the amount of blood in the ventricles just before systole. EDV was measured by CMR at indicated time points. Baseline was considered as the latest assessment prior to first administration of either study drug, i.e. CPHPC or anti-SAP mAb. Change from Baseline was calculated as post-dose visit value minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. 88888 indicates data is not available, as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -1) and Session 2 to 5: Day 24; 8 week follow-up; 6 months follow-up
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [82]
    1 [83]
    Units: Milliliter
    arithmetic mean (standard deviation)
        Session 2, Day 24, n=6,0
    -3.473 ( 11.2584 )
    99999 ( 99999 )
        Session 3, Day 24, n=6,0
    1.653 ( 7.3322 )
    99999 ( 99999 )
        Session 4, Day 24, n=5,0
    -5.262 ( 5.3765 )
    99999 ( 99999 )
        Session 5, Day 24, n=4,0
    -9.323 ( 11.5275 )
    99999 ( 99999 )
        8 Week follow-up, n=6,1
    9.887 ( 19.3925 )
    -4.560 ( 88888 )
        6 month follow-up, n=2,0
    -21.030 ( 8.0469 )
    99999 ( 99999 )
    Notes
    [82] - Safety Population
    [83] - Safety Population
    No statistical analyses for this end point

    Secondary: Change from Baseline in left ventricle End Diastolic Volume (EDV) by ECHO

    Close Top of page
    End point title
    Change from Baseline in left ventricle End Diastolic Volume (EDV) by ECHO
    End point description
    Left ventricle EDV is the volume of blood in the left ventricle at end load or filling in (diastole) or the amount of blood in the ventricles just before systole. EDV was measured by ECHO at indicated time points. Baseline was considered as the latest assessment prior to first administration of either study drug, i.e. CPHPC or anti-SAP mAb. Change from Baseline was calculated as post-dose visit value minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. 88888 indicates data is not available, as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -1) and Session 1 to 6: Day 24; 8 week follow-up; 6 months follow-up
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [84]
    1 [85]
    Units: Milliliter
    arithmetic mean (standard deviation)
        Session 1, Day 24, n=6,1
    0.050 ( 4.6276 )
    -1.790 ( 88888 )
        Session 2, Day 24, n=6,0
    -2.940 ( 10.2320 )
    99999 ( 99999 )
        Session 3, Day 24, n=6,0
    -2.922 ( 14.0019 )
    99999 ( 99999 )
        Session 4, Day 24, n=5,0
    -12.338 ( 10.2249 )
    99999 ( 99999 )
        Session 5, Day 24, n=4,0
    -11.860 ( 14.5676 )
    99999 ( 99999 )
        Session 6, Day 24, n=4,0
    -5.073 ( 11.3679 )
    99999 ( 99999 )
        8 Week follow-up, n=6,1
    -7.648 ( 4.4630 )
    -7.100 ( 88888 )
        6 month follow-up, n=4,0
    -12.045 ( 20.2972 )
    99999 ( 99999 )
    Notes
    [84] - Safety Population
    [85] - Safety Population
    No statistical analyses for this end point

    Secondary: Change from Baseline in ratio of mitral peak velocity of early filling to early diastolic mitral annual velocity (E/e' ratio)

    Close Top of page
    End point title
    Change from Baseline in ratio of mitral peak velocity of early filling to early diastolic mitral annual velocity (E/e' ratio)
    End point description
    E/e' ratio was measured by ECHO at indicated time points. It had 2 separate measurements: lateral and septal. Baseline was considered as the latest assessment prior to first administration of either study drug, i.e. CPHPC or anti-SAP mAb. Change from Baseline was calculated as post-dose visit value minus Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. 88888 indicates data is not available, as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -1) and Session 1 to 6: Day 24; 8 week follow-up; 6 months follow-up
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [86]
    1 [87]
    Units: Ratio
    arithmetic mean (standard deviation)
        E/e Lateral Ratio, Session 1, Day 24, n=6,1
    -1.55 ( 2.813 )
    -2.80 ( 88888 )
        E/e Lateral Ratio, Session 2, Day 24, n=6,0
    -0.77 ( 3.555 )
    99999 ( 99999 )
        E/e Lateral Ratio, Session 3, Day 24, n=6,0
    3.20 ( 2.197 )
    99999 ( 99999 )
        E/e Lateral Ratio, Session 4, Day 24, n=5,0
    -0.64 ( 4.750 )
    99999 ( 99999 )
        E/e Lateral Ratio, Session 5, Day 24, n=4,0
    1.22 ( 5.134 )
    99999 ( 99999 )
        E/e Lateral Ratio, Session 6, Day 24, n=4,0
    3.25 ( 2.300 )
    99999 ( 99999 )
        E/e Lateral Ratio, 8 Week follow-up, n=6,1
    0.05 ( 2.681 )
    2.90 ( 88888 )
        E/e Lateral Ratio, 6 month follow-up, n=4,0
    -0.58 ( 4.442 )
    99999 ( 99999 )
        E/e Septal Ratio, Session 1, Day 24, n=6,1
    0.50 ( 2.995 )
    -2.00 ( 88888 )
        E/e Septal Ratio, Session 2, Day 24, n=6,0
    0.52 ( 4.640 )
    99999 ( 99999 )
        E/e Septal Ratio, Session 3, Day 24, n=6,0
    5.33 ( 5.136 )
    99999 ( 99999 )
        E/e Septal Ratio, Session 4, Day 24, n=5,0
    2.96 ( 3.462 )
    99999 ( 99999 )
        E/e Septal Ratio, Session 5, Day 24, n=4,0
    4.48 ( 3.010 )
    99999 ( 99999 )
        E/e Septal Ratio, Session 6, Day 24, n=4,0
    6.23 ( 5.917 )
    99999 ( 99999 )
        E/e Septal Ratio, 8 Week follow-up, n=6,0
    2.83 ( 4.236 )
    99999 ( 99999 )
        E/e Septal Ratio, 6 month follow-up, n=4,0
    4.95 ( 1.708 )
    99999 ( 99999 )
    Notes
    [86] - Safety Population
    [87] - Safety Population
    No statistical analyses for this end point

    Secondary: Change from Baseline in plasma cytokines over time

    Close Top of page
    End point title
    Change from Baseline in plasma cytokines over time
    End point description
    Blood samples were collected for assessment of plasma cytokines biomarkers which included Tumor Necrosis Factor (TNF), Interleukin 1 beta (IL-1 beta), IL-6, IL-10, Interferon gamma (INF gamma), IL-12, IL-13, IL-2, IL-4 and IL-8. Baseline was considered as the latest assessment prior to first administration of either study drug, i.e. CPHPC or anti-SAP mAb. Change from Baseline was calculated as post-dose visit value minus Baseline value. Absolute values below the lower limit of quantification (LLQ) were imputed with half the LLQ and those above the upper limit of quantification (ULQ) were imputed with the ULQ. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles). 99999 indicates data is not available. 88888 indicates data is not available, as standard deviation could not be calculated as only one participant was analyzed.
    End point type
    Secondary
    End point timeframe
    Baseline (Day -1) and Session 1: Day 1 (predose, 1,3,6 hours), Day 2, Day 3 (predose, 1,3,6 hours), Day 4, Day 5; Session 2 to 6: Day -2, Day 1 (predose, 1,3,6 hours), Day 2, Day 3 (predose, 1,3,6 hours), Day 4, Day 5
    End point values
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants Group 2: Post-chemotherapy AL Amyloidosis participants
    Number of subjects analysed
    6 [88]
    1 [89]
    Units: Nanograms per liter (ng/L)
    arithmetic mean (standard deviation)
        IL-1 beta, Session 1, Day 1, predose, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-1 beta, Session 1, Day 1, 1 hour, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-1 beta, Session 1, Day 1, 3 hour, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-1 beta, Session 1, Day 1, 6 hour, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-1 beta, Session 1, Day 2, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-1 beta, Session 1, Day 3, predose, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-1 beta, Session 1, Day 3, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 1, Day 3, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 1, Day 3, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 1, Day 4, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 1, Day 5, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 2, Day -2, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 2, Day 1, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 2, Day 1, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 2, Day 1, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 2, Day 1, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 2, Day 2, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 2, Day 3, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 2, Day 3, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 2, Day 3, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 2, Day 3, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 2, Day 4, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 2, Day 5, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 3, Day -2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 3, Day 1, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 3, Day 1, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 3, Day 1, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 3, Day 1, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 3, Day 2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 3, Day 3, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 3, Day 3, 1 hour, n=6,0
    0.293 ( 0.7185 )
    99999 ( 99999 )
        IL-1 beta, Session 3, Day 3, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 3, Day 3, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 3, Day 4, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 3, Day 5, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 4, Day -2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 4, Day 1, predose, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 4, Day 1, 1 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 4, Day 1, 3 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 4, Day 1, 6 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 4, Day 2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 4, Day 3, predose, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 4, Day 3, 1 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 4, Day 3, 3 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 4, Day 3, 6 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 4, Day 4, n=5,0
    0.504 ( 1.1270 )
    99999 ( 99999 )
        IL-1 beta, Session 4, Day 5, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 5, Day -2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 5, Day 1, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 5, Day 1, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 5, Day 1, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 5, Day 1, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 5, Day 2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 5, Day 3, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 5, Day 3, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 5, Day 3, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 5, Day 3, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 5, Day 4, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 5, Day 5, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 6, Day -2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 6, Day 1, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 6, Day 1, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 6, Day 1, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 6, Day 1, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 6, Day 2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 6, Day 3, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 6, Day 3, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 6, Day 3, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 6, Day 3, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 6, Day 4, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-1 beta, Session 6, Day 5, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-6, Session 1, Day 1, predose, n=6,1
    0.275 ( 0.4711 )
    0.000 ( 88888 )
        IL-6, Session 1, Day 1, 1 hour, n=6,1
    -0.080 ( 0.7723 )
    0.000 ( 88888 )
        IL-6, Session 1, Day 1, 3 hour, n=6,1
    -0.727 ( 1.2035 )
    0.000 ( 88888 )
        IL-6, Session 1, Day 1, 6 hour, n=6,1
    -1.077 ( 1.2511 )
    2.880 ( 88888 )
        IL-6, Session 1, Day 2, n=6,1
    6.278 ( 6.3567 )
    29.030 ( 88888 )
        IL-6, Session 1, Day 3, predose, n=6,1
    7.688 ( 8.8639 )
    16.980 ( 88888 )
        IL-6, Session 1, Day 3, 1 hour, n=6,0
    6.857 ( 10.5934 )
    99999 ( 99999 )
        IL-6, Session 1, Day 3, 3 hour, n=6,0
    0.827 ( 3.5790 )
    99999 ( 99999 )
        IL-6, Session 1, Day 3, 6 hour, n=6,0
    0.932 ( 5.5637 )
    99999 ( 99999 )
        IL-6, Session 1, Day 4, n=6,0
    5.453 ( 3.6039 )
    99999 ( 99999 )
        IL-6, Session 1, Day 5, n=6,0
    3.245 ( 3.3934 )
    99999 ( 99999 )
        IL-6, Session 2, Day -2, n=6,0
    0.393 ( 0.5250 )
    99999 ( 99999 )
        IL-6, Session 2, Day 1, predose, n=6,0
    0.632 ( 1.2026 )
    99999 ( 99999 )
        IL-6, Session 2, Day 1, 1 hour, n=6,0
    0.025 ( 0.7117 )
    99999 ( 99999 )
        IL-6, Session 2, Day 1, 3 hour, n=6,0
    -0.860 ( 1.0909 )
    99999 ( 99999 )
        IL-6, Session 2, Day 1, 6 hour, n=6,0
    -0.282 ( 1.7148 )
    99999 ( 99999 )
        IL-6, Session 2, Day 2, n=6,0
    21.590 ( 27.1214 )
    99999 ( 99999 )
        IL-6, Session 2, Day 3, predose, n=6,0
    11.365 ( 11.4140 )
    99999 ( 99999 )
        IL-6, Session 2, Day 3, 1 hour, n=6,0
    7.517 ( 8.6084 )
    99999 ( 99999 )
        IL-6, Session 2, Day 3, 3 hour, n=6,0
    3.460 ( 5.0176 )
    99999 ( 99999 )
        IL-6, Session 2, Day 3, 6 hour, n=6,0
    0.723 ( 4.5392 )
    99999 ( 99999 )
        IL-6, Session 2, Day 4, n=6,0
    4.580 ( 5.9326 )
    99999 ( 99999 )
        IL-6, Session 2, Day 5, n=6,0
    6.395 ( 5.2800 )
    99999 ( 99999 )
        IL-6, Session 3, Day -2, n=5,0
    0.148 ( 0.8211 )
    99999 ( 99999 )
        IL-6, Session 3, Day 1, predose, n=6,0
    0.782 ( 1.5023 )
    99999 ( 99999 )
        IL-6, Session 3, Day 1, 1 hour, n=6,0
    0.268 ( 1.4865 )
    99999 ( 99999 )
        IL-6, Session 3, Day 1, 3 hour, n=6,0
    0.062 ( 2.5899 )
    99999 ( 99999 )
        IL-6, Session 3, Day 1, 6 hour, n=6,0
    -0.918 ( 1.2591 )
    99999 ( 99999 )
        IL-6, Session 3, Day 2, n=5,0
    17.608 ( 29.2558 )
    99999 ( 99999 )
        IL-6, Session 3, Day 3, predose, n=6,0
    11.872 ( 8.7413 )
    99999 ( 99999 )
        IL-6, Session 3, Day 3, 1 hour, n=6,0
    5.835 ( 3.8271 )
    99999 ( 99999 )
        IL-6, Session 3, Day 3, 3 hour, n=6,0
    1.742 ( 1.9174 )
    99999 ( 99999 )
        IL-6, Session 3, Day 3, 6 hour, n=6,0
    0.063 ( 2.2072 )
    99999 ( 99999 )
        IL-6, Session 3, Day 4, n=6,0
    4.667 ( 6.9875 )
    99999 ( 99999 )
        IL-6, Session 3, Day 5, n=6,0
    5.570 ( 2.6004 )
    99999 ( 99999 )
        IL-6, Session 4, Day -2, n=5,0
    0.892 ( 0.8423 )
    99999 ( 99999 )
        IL-6, Session 4, Day 1, predose, n=5,0
    1.486 ( 0.8702 )
    99999 ( 99999 )
        IL-6, Session 4, Day 1, 1 hour, n=5,0
    0.926 ( 0.7103 )
    99999 ( 99999 )
        IL-6, Session 4, Day 1, 3 hour, n=5,0
    -0.026 ( 0.1599 )
    99999 ( 99999 )
        IL-6, Session 4, Day 1, 6 hour, n=5,0
    -1.028 ( 1.3685 )
    99999 ( 99999 )
        IL-6, Session 4, Day 2, n=5,0
    5.720 ( 11.3851 )
    99999 ( 99999 )
        IL-6, Session 4, Day 3, predose, n=5,0
    10.924 ( 6.5370 )
    99999 ( 99999 )
        IL-6, Session 4, Day 3, 1 hour, n=5,0
    4.486 ( 2.0420 )
    99999 ( 99999 )
        IL-6, Session 4, Day 3, 3 hour, n=5,0
    1.446 ( 1.5368 )
    99999 ( 99999 )
        IL-6, Session 4, Day 3, 6 hour, n=5,0
    -0.116 ( 1.7948 )
    99999 ( 99999 )
        IL-6, Session 4, Day 4, n=5,0
    5.756 ( 6.8645 )
    99999 ( 99999 )
        IL-6, Session 4, Day 5, n=4,0
    4.388 ( 3.7765 )
    99999 ( 99999 )
        IL-6, Session 5, Day -2, n=4,0
    0.027 ( 0.8164 )
    99999 ( 99999 )
        IL-6, Session 5, Day 1, predose, n=4,0
    0.865 ( 0.9927 )
    99999 ( 99999 )
        IL-6, Session 5, Day 1, 1 hour, n=4,0
    -0.007 ( 1.3219 )
    99999 ( 99999 )
        IL-6, Session 5, Day 1, 3 hour, n=4,0
    -0.423 ( 1.5816 )
    99999 ( 99999 )
        IL-6, Session 5, Day 1, 6 hour, n=4,0
    -1.213 ( 1.5189 )
    99999 ( 99999 )
        IL-6, Session 5, Day 2, n=4,0
    0.905 ( 4.0920 )
    99999 ( 99999 )
        IL-6, Session 5, Day 3, predose, n=4,0
    7.323 ( 4.8265 )
    99999 ( 99999 )
        IL-6, Session 5, Day 3, 1 hour, n=4,0
    4.240 ( 3.6214 )
    99999 ( 99999 )
        IL-6, Session 5, Day 3, 3 hour, n=4,0
    -0.125 ( 0.7543 )
    99999 ( 99999 )
        IL-6, Session 5, Day 3, 6 hour, n=4,0
    -1.390 ( 1.3301 )
    99999 ( 99999 )
        IL-6, Session 5, Day 4, n=4,0
    3.598 ( 5.7476 )
    99999 ( 99999 )
        IL-6, Session 5, Day 5, n=4,0
    6.533 ( 2.6812 )
    99999 ( 99999 )
        IL-6, Session 6, Day -2, n=4,0
    1.383 ( 1.8535 )
    99999 ( 99999 )
        IL-6, Session 6, Day 1, predose, n=4,0
    0.565 ( 1.4007 )
    99999 ( 99999 )
        IL-6, Session 6, Day 1, 1 hour, n=4,0
    0.077 ( 1.1200 )
    99999 ( 99999 )
        IL-6, Session 6, Day 1, 3 hour, n=4,0
    -0.413 ( 1.4416 )
    99999 ( 99999 )
        IL-6, Session 6, Day 1, 6 hour, n=4,0
    -1.165 ( 0.9786 )
    99999 ( 99999 )
        IL-6, Session 6, Day 2, n=4,0
    0.932 ( 4.0340 )
    99999 ( 99999 )
        IL-6, Session 6, Day 3, predose, n=4,0
    15.008 ( 13.0010 )
    99999 ( 99999 )
        IL-6, Session 6, Day 3, 1 hour, n=4,0
    10.083 ( 9.2076 )
    99999 ( 99999 )
        IL-6, Session 6, Day 3, 3 hour, n=4,0
    1.435 ( 1.7505 )
    99999 ( 99999 )
        IL-6, Session 6, Day 3, 6 hour, n=4,0
    -1.005 ( 1.3522 )
    99999 ( 99999 )
        IL-6, Session 6, Day 4, n=4,0
    1.740 ( 3.2649 )
    99999 ( 99999 )
        IL-6, Session 6, Day 5, n=4,0
    7.190 ( 3.8811 )
    99999 ( 99999 )
        IL-10, Session 1, Day 1, predose, n=6,1
    -0.067 ( 0.1633 )
    0.000 ( 88888 )
        IL-10, Session 1, Day 1, 1 hour, n=6,1
    0.105 ( 0.1663 )
    8.580 ( 88888 )
        IL-10, Session 1, Day 1, 3 hour, n=6,1
    0.763 ( 0.4804 )
    5.260 ( 88888 )
        IL-10, Session 1, Day 1, 6 hour, n=6,1
    1.710 ( 1.4719 )
    6.020 ( 88888 )
        IL-10, Session 1, Day 2, n=6,1
    -0.005 ( 0.2436 )
    1.150 ( 88888 )
        IL-10, Session 1, Day 3, predose, n=6,1
    0.040 ( 0.3347 )
    1.280 ( 88888 )
        IL-10, Session 1, Day 3, 1 hour, n=6,0
    0.670 ( 1.0153 )
    99999 ( 99999 )
        IL-10, Session 1, Day 3, 3 hour, n=6,0
    0.065 ( 0.3896 )
    99999 ( 99999 )
        IL-10, Session 1, Day 3, 6 hour, n=6,0
    0.002 ( 0.0041 )
    99999 ( 99999 )
        IL-10, Session 1, Day 4, n=6,0
    -0.067 ( 0.1633 )
    99999 ( 99999 )
        IL-10, Session 1, Day 5, n=6,0
    -0.067 ( 0.1633 )
    99999 ( 99999 )
        IL-10, Session 2, Day -2, n=6,0
    -0.067 ( 0.1633 )
    99999 ( 99999 )
        IL-10, Session 2, Day 1, predose, n=6,0
    0.002 ( 0.0041 )
    99999 ( 99999 )
        IL-10, Session 2, Day 1, 1 hour, n=6,0
    0.612 ( 0.8293 )
    99999 ( 99999 )
        IL-10, Session 2, Day 1, 3 hour, n=6,0
    1.132 ( 1.1748 )
    99999 ( 99999 )
        IL-10, Session 2, Day 1, 6 hour, n=6,0
    0.785 ( 0.5189 )
    99999 ( 99999 )
        IL-10, Session 2, Day 2, n=6,0
    0.012 ( 0.2757 )
    99999 ( 99999 )
        IL-10, Session 2, Day 3, predose, n=6,0
    0.233 ( 0.5618 )
    99999 ( 99999 )
        IL-10, Session 2, Day 3, 1 hour, n=6,0
    0.775 ( 1.1274 )
    99999 ( 99999 )
        IL-10, Session 2, Day 3, 3 hour, n=6,0
    0.782 ( 0.8451 )
    99999 ( 99999 )
        IL-10, Session 2, Day 3, 6 hour, n=6,0
    0.015 ( 0.0367 )
    99999 ( 99999 )
        IL-10, Session 2, Day 4, n=6,0
    -0.005 ( 0.0122 )
    99999 ( 99999 )
        IL-10, Session 2, Day 5, n=6,0
    0.110 ( 0.2122 )
    99999 ( 99999 )
        IL-10, Session 3, Day -2, n=5,0
    0.032 ( 0.3422 )
    99999 ( 99999 )
        IL-10, Session 3, Day 1, predose, n=6,0
    -0.067 ( 0.1633 )
    99999 ( 99999 )
        IL-10, Session 3, Day 1, 1 hour, n=6,0
    0.228 ( 0.2328 )
    99999 ( 99999 )
        IL-10, Session 3, Day 1, 3 hour, n=6,0
    1.185 ( 1.1559 )
    99999 ( 99999 )
        IL-10, Session 3, Day 1, 6 hour, n=6,0
    0.495 ( 0.6641 )
    99999 ( 99999 )
        IL-10, Session 3, Day 2, n=5,0
    -0.080 ( 0.1789 )
    99999 ( 99999 )
        IL-10, Session 3, Day 3, predose, n=6,0
    -0.067 ( 0.1633 )
    99999 ( 99999 )
        IL-10, Session 3, Day 3, 1 hour, n=6,0
    0.450 ( 0.6048 )
    99999 ( 99999 )
        IL-10, Session 3, Day 3, 3 hour, n=6,0
    0.322 ( 0.5322 )
    99999 ( 99999 )
        IL-10, Session 3, Day 3, 6 hour, n=6,0
    0.092 ( 0.1542 )
    99999 ( 99999 )
        IL-10, Session 3, Day 4, n=6,0
    -0.067 ( 0.1633 )
    99999 ( 99999 )
        IL-10, Session 3, Day 5, n=6,0
    -0.067 ( 0.1633 )
    99999 ( 99999 )
        IL-10, Session 4, Day -2, n=5,0
    -0.080 ( 0.1789 )
    99999 ( 99999 )
        IL-10, Session 4, Day 1, predose, n=5,0
    -0.080 ( 0.1789 )
    99999 ( 99999 )
        IL-10, Session 4, Day 1, 1 hour, n=5,0
    0.758 ( 1.4466 )
    99999 ( 99999 )
        IL-10, Session 4, Day 1, 3 hour, n=5,0
    3.868 ( 6.3123 )
    99999 ( 99999 )
        IL-10, Session 4, Day 1, 6 hour, n=5,0
    0.868 ( 0.9281 )
    99999 ( 99999 )
        IL-10, Session 4, Day 2, n=5,0
    -0.080 ( 0.1789 )
    99999 ( 99999 )
        IL-10, Session 4, Day 3, predose, n=5,0
    0.022 ( 0.0492 )
    99999 ( 99999 )
        IL-10, Session 4, Day 3, 1 hour, n=5,0
    0.808 ( 1.0592 )
    99999 ( 99999 )
        IL-10, Session 4, Day 3, 3 hour, n=5,0
    0.598 ( 0.6549 )
    99999 ( 99999 )
        IL-10, Session 4, Day 3, 6 hour, n=5,0
    0.184 ( 0.4284 )
    99999 ( 99999 )
        IL-10, Session 4, Day 4, n=5,0
    -0.080 ( 0.1789 )
    99999 ( 99999 )
        IL-10, Session 4, Day 5, n=4,0
    -0.100 ( 0.2000 )
    99999 ( 99999 )
        IL-10, Session 5, Day -2, n=4,0
    -0.100 ( 0.2000 )
    99999 ( 99999 )
        IL-10, Session 5, Day 1, predose, n=4,0
    -0.100 ( 0.2000 )
    99999 ( 99999 )
        IL-10, Session 5, Day 1, 1 hour, n=4,0
    2.485 ( 4.8507 )
    99999 ( 99999 )
        IL-10, Session 5, Day 1, 3 hour, n=4,0
    3.828 ( 6.5828 )
    99999 ( 99999 )
        IL-10, Session 5, Day 1, 6 hour, n=4,0
    1.120 ( 1.5607 )
    99999 ( 99999 )
        IL-10, Session 5, Day 2, n=4,0
    -0.100 ( 0.2000 )
    99999 ( 99999 )
        IL-10, Session 5, Day 3, predose, n=4,0
    0.393 ( 0.4774 )
    99999 ( 99999 )
        IL-10, Session 5, Day 3, 1 hour, n=4,0
    0.950 ( 0.9330 )
    99999 ( 99999 )
        IL-10, Session 5, Day 3, 3 hour, n=4,0
    1.060 ( 0.9783 )
    99999 ( 99999 )
        IL-10, Session 5, Day 3, 6 hour, n=4,0
    0.663 ( 0.6663 )
    99999 ( 99999 )
        IL-10, Session 5, Day 4, n=4,0
    0.210 ( 0.4267 )
    99999 ( 99999 )
        IL-10, Session 5, Day 5, n=4,0
    0.025 ( 0.0500 )
    99999 ( 99999 )
        IL-10, Session 6, Day -2, n=4,0
    -0.100 ( 0.2000 )
    99999 ( 99999 )
        IL-10, Session 6, Day 1, predose, n=4,0
    -0.100 ( 0.2000 )
    99999 ( 99999 )
        IL-10, Session 6, Day 1, 1 hour, n=4,0
    0.333 ( 0.9506 )
    99999 ( 99999 )
        IL-10, Session 6, Day 1, 3 hour, n=4,0
    1.738 ( 2.5365 )
    99999 ( 99999 )
        IL-10, Session 6, Day 1, 6 hour, n=4,0
    1.418 ( 1.7245 )
    99999 ( 99999 )
        IL-10, Session 6, Day 2, n=4,0
    -0.100 ( 0.2000 )
    99999 ( 99999 )
        IL-10, Session 6, Day 3, predose, n=4,0
    0.015 ( 0.0300 )
    99999 ( 99999 )
        IL-10, Session 6, Day 3, 1 hour, n=4,0
    0.753 ( 1.4004 )
    99999 ( 99999 )
        IL-10, Session 6, Day 3, 3 hour, n=4,0
    0.675 ( 1.1466 )
    99999 ( 99999 )
        IL-10, Session 6, Day 3, 6 hour, n=4,0
    0.220 ( 0.2723 )
    99999 ( 99999 )
        IL-10, Session 6, Day 4, n=4,0
    -0.100 ( 0.2000 )
    99999 ( 99999 )
        IL-10, Session 6, Day 5, n=4,0
    0.023 ( 0.0450 )
    99999 ( 99999 )
        TNF, Session 1, Day 1, predose, n=6,1
    0.055 ( 0.4378 )
    0.320 ( 88888 )
        TNF, Session 1, Day 1, 1 hour, n=6,1
    0.007 ( 0.7159 )
    0.100 ( 88888 )
        TNF, Session 1, Day 1, 3 hour, n=6,1
    -0.180 ( 0.7430 )
    0.880 ( 88888 )
        TNF, Session 1, Day 1, 6 hour, n=6,1
    -0.132 ( 0.8145 )
    2.300 ( 88888 )
        TNF, Session 1, Day 2, n=6,1
    1.920 ( 1.5379 )
    5.130 ( 88888 )
        TNF, Session 1, Day 3, predose, n=6,1
    1.453 ( 1.3405 )
    3.010 ( 88888 )
        TNF, Session 1, Day 3, 1 hour, n=6,0
    1.240 ( 0.9968 )
    99999 ( 99999 )
        TNF, Session 1, Day 3, 3 hour, n=6,0
    0.797 ( 1.0229 )
    99999 ( 99999 )
        TNF, Session 1, Day 3, 6 hour, n=6,0
    0.460 ( 0.9373 )
    99999 ( 99999 )
        TNF, Session 1, Day 4, n=6,0
    1.088 ( 1.2874 )
    99999 ( 99999 )
        TNF, Session 1, Day 5, n=6,0
    1.577 ( 1.5915 )
    99999 ( 99999 )
        TNF, Session 2, Day -2, n=6,0
    0.167 ( 0.9735 )
    99999 ( 99999 )
        TNF, Session 2, Day 1, predose, n=6,0
    0.233 ( 0.8351 )
    99999 ( 99999 )
        TNF, Session 2, Day 1, 1 hour, n=6,0
    0.133 ( 1.0259 )
    99999 ( 99999 )
        TNF, Session 2, Day 1, 3 hour, n=6,0
    0.015 ( 1.0940 )
    99999 ( 99999 )
        TNF, Session 2, Day 1, 6 hour, n=6,0
    -0.100 ( 1.2625 )
    99999 ( 99999 )
        TNF, Session 2, Day 2, n=6,0
    1.523 ( 1.6646 )
    99999 ( 99999 )
        TNF, Session 2, Day 3, predose, n=6,0
    2.143 ( 1.5642 )
    99999 ( 99999 )
        TNF, Session 2, Day 3, 1 hour, n=6,0
    1.682 ( 1.3855 )
    99999 ( 99999 )
        TNF, Session 2, Day 3, 3 hour, n=6,0
    1.133 ( 0.9970 )
    99999 ( 99999 )
        TNF, Session 2, Day 3, 6 hour, n=6,0
    0.503 ( 1.0718 )
    99999 ( 99999 )
        TNF, Session 2, Day 4, n=6,0
    1.397 ( 2.1712 )
    99999 ( 99999 )
        TNF, Session 2, Day 5, n=6,0
    1.968 ( 1.4560 )
    99999 ( 99999 )
        TNF, Session 3, Day -2, n=5,0
    0.098 ( 1.2163 )
    99999 ( 99999 )
        TNF, Session 3, Day 1, predose, n=6,0
    0.497 ( 0.9650 )
    99999 ( 99999 )
        TNF, Session 3, Day 1, 1 hour, n=6,0
    -0.297 ( 0.9572 )
    99999 ( 99999 )
        TNF, Session 3, Day 1, 3 hour, n=6,0
    -0.198 ( 0.9246 )
    99999 ( 99999 )
        TNF, Session 3, Day 1, 6 hour, n=6,0
    -0.167 ( 1.2317 )
    99999 ( 99999 )
        TNF, Session 3, Day 2, n=5,0
    0.446 ( 1.1212 )
    99999 ( 99999 )
        TNF, Session 3, Day 3, predose, n=6,0
    1.267 ( 1.1583 )
    99999 ( 99999 )
        TNF, Session 3, Day 3, 1 hour, n=6,0
    0.513 ( 1.1234 )
    99999 ( 99999 )
        TNF, Session 3, Day 3, 3 hour, n=6,0
    0.128 ( 1.0706 )
    99999 ( 99999 )
        TNF, Session 3, Day 3, 6 hour, n=6,0
    0.233 ( 1.2605 )
    99999 ( 99999 )
        TNF, Session 3, Day 4, n=6,0
    0.585 ( 1.6017 )
    99999 ( 99999 )
        TNF, Session 3, Day 5, n=6,0
    0.997 ( 1.3819 )
    99999 ( 99999 )
        TNF, Session 4, Day -2, n=5,0
    -0.208 ( 0.5949 )
    99999 ( 99999 )
        TNF, Session 4, Day 1, predose, n=5,0
    -0.214 ( 0.8527 )
    99999 ( 99999 )
        TNF, Session 4, Day 1, 1 hour, n=5,0
    0.160 ( 1.5494 )
    99999 ( 99999 )
        TNF, Session 4, Day 1, 3 hour, n=5,0
    0.218 ( 1.5011 )
    99999 ( 99999 )
        TNF, Session 4, Day 1, 6 hour, n=5,0
    -0.412 ( 1.1373 )
    99999 ( 99999 )
        TNF, Session 4, Day 2, n=5,0
    -0.122 ( 0.6977 )
    99999 ( 99999 )
        TNF, Session 4, Day 3, predose, n=5,0
    0.606 ( 0.5265 )
    99999 ( 99999 )
        TNF, Session 4, Day 3, 1 hour, n=5,0
    0.100 ( 0.5074 )
    99999 ( 99999 )
        TNF, Session 4, Day 3, 3 hour, n=5,0
    0.098 ( 0.7172 )
    99999 ( 99999 )
        TNF, Session 4, Day 3, 6 hour, n=5,0
    -0.702 ( 0.5368 )
    99999 ( 99999 )
        TNF, Session 4, Day 4, n=5,0
    -0.270 ( 0.7576 )
    99999 ( 99999 )
        TNF, Session 4, Day 5, n=4,0
    0.095 ( 0.4456 )
    99999 ( 99999 )
        TNF, Session 5, Day -2, n=4,0
    -0.350 ( 0.5814 )
    99999 ( 99999 )
        TNF, Session 5, Day 1, predose, n=4,0
    -0.320 ( 0.6703 )
    99999 ( 99999 )
        TNF, Session 5, Day 1, 1 hour, n=4,0
    -0.130 ( 1.2227 )
    99999 ( 99999 )
        TNF, Session 5, Day 1, 3 hour, n=4,0
    -0.055 ( 1.0728 )
    99999 ( 99999 )
        TNF, Session 5, Day 1, 6 hour, n=4,0
    -0.513 ( 1.1003 )
    99999 ( 99999 )
        TNF, Session 5, Day 2, n=4,0
    -0.498 ( 0.9752 )
    99999 ( 99999 )
        TNF, Session 5, Day 3, predose, n=4,0
    0.147 ( 0.8951 )
    99999 ( 99999 )
        TNF, Session 5, Day 3, 1 hour, n=4,0
    -0.188 ( 0.7406 )
    99999 ( 99999 )
        TNF, Session 5, Day 3, 3 hour, n=4,0
    -0.378 ( 0.9306 )
    99999 ( 99999 )
        TNF, Session 5, Day 3, 6 hour, n=4,0
    -0.630 ( 0.7857 )
    99999 ( 99999 )
        TNF, Session 5, Day 4, n=4,0
    -0.100 ( 1.0725 )
    99999 ( 99999 )
        TNF, Session 5, Day 5, n=4,0
    0.168 ( 0.3909 )
    99999 ( 99999 )
        TNF, Session 6, Day -2, n=4,0
    -0.428 ( 1.3664 )
    99999 ( 99999 )
        TNF, Session 6, Day 1, predose, n=4,0
    -0.238 ( 1.3158 )
    99999 ( 99999 )
        TNF, Session 6, Day 1, 1 hour, n=4,0
    -0.303 ( 1.3853 )
    99999 ( 99999 )
        TNF, Session 6, Day 1, 3 hour, n=4,0
    -0.145 ( 1.8684 )
    99999 ( 99999 )
        TNF, Session 6, Day 1, 6 hour, n=4,0
    -0.500 ( 1.4020 )
    99999 ( 99999 )
        TNF, Session 6, Day 2, n=4,0
    -0.000 ( 1.3253 )
    99999 ( 99999 )
        TNF, Session 6, Day 3, predose, n=4,0
    0.278 ( 1.9987 )
    99999 ( 99999 )
        TNF, Session 6, Day 3, 1 hour, n=4,0
    -0.195 ( 1.6007 )
    99999 ( 99999 )
        TNF, Session 6, Day 3, 3 hour, n=4,0
    -0.385 ( 1.4669 )
    99999 ( 99999 )
        TNF, Session 6, Day 3, 6 hour, n=4,0
    -0.585 ( 1.3026 )
    99999 ( 99999 )
        TNF, Session 6, Day 4, n=4,0
    -0.368 ( 1.1280 )
    99999 ( 99999 )
        TNF, Session 6, Day 5, n=4,0
    0.322 ( 1.2795 )
    99999 ( 99999 )
        INF gamma, Session 1, Day 1, predose, n=6,1
    0.075 ( 1.6224 )
    1.860 ( 88888 )
        INF gamma, Session 1, Day 1, 1 hour, n=6,1
    -1.373 ( 2.1255 )
    0.000 ( 88888 )
        INF gamma, Session 1, Day 1, 3 hour, n=6,1
    -3.298 ( 3.1409 )
    0.000 ( 88888 )
        INF gamma, Session 1, Day 1, 6 hour, n=6,1
    -3.298 ( 3.1409 )
    0.000 ( 88888 )
        INF gamma, Session 1, Day 2, n=6,1
    1.713 ( 7.5955 )
    1.930 ( 88888 )
        INF gamma, Session 1, Day 3, predose, n=6,1
    17.122 ( 27.3980 )
    0.000 ( 88888 )
        INF gamma, Session 1, Day 3, 1 hour, n=6,0
    12.118 ( 22.0807 )
    99999 ( 99999 )
        INF gamma, Session 1, Day 3, 3 hour, n=6,0
    7.150 ( 18.4949 )
    99999 ( 99999 )
        INF gamma, Session 1, Day 3, 6 hour, n=6,0
    0.538 ( 8.5114 )
    99999 ( 99999 )
        INF gamma, Session 1, Day 4, n=6,0
    3.242 ( 12.2847 )
    99999 ( 99999 )
        INF gamma, Session 1, Day 5, n=6,0
    19.502 ( 38.3215 )
    99999 ( 99999 )
        INF gamma, Session 2, Day -2, n=6,0
    -1.045 ( 3.4175 )
    99999 ( 99999 )
        INF gamma, Session 2, Day 1, predose, n=6,0
    0.452 ( 3.5018 )
    99999 ( 99999 )
        INF gamma, Session 2, Day 1, 1 hour, n=6,0
    0.145 ( 3.2180 )
    99999 ( 99999 )
        INF gamma, Session 2, Day 1, 3 hour, n=6,0
    -1.833 ( 1.3991 )
    99999 ( 99999 )
        INF gamma, Session 2, Day 1, 6 hour, n=6,0
    -3.072 ( 2.6378 )
    99999 ( 99999 )
        INF gamma, Session 2, Day 2, n=6,0
    -2.660 ( 3.5043 )
    99999 ( 99999 )
        INF gamma, Session 2, Day 3, predose, n=6,0
    -1.045 ( 2.2260 )
    99999 ( 99999 )
        INF gamma, Session 2, Day 3, 1 hour, n=6,0
    -1.580 ( 2.5672 )
    99999 ( 99999 )
        INF gamma, Session 2, Day 3, 3 hour, n=6,0
    -2.473 ( 2.5631 )
    99999 ( 99999 )
        INF gamma, Session 2, Day 3, 6 hour, n=6,0
    -3.298 ( 3.1409 )
    99999 ( 99999 )
        INF gamma, Session 2, Day 4, n=6,0
    -2.572 ( 3.4040 )
    99999 ( 99999 )
        INF gamma, Session 2, Day 5, n=6,0
    -1.993 ( 2.8977 )
    99999 ( 99999 )
        INF gamma, Session 3, Day -2, n=5,0
    -2.190 ( 3.9839 )
    99999 ( 99999 )
        INF gamma, Session 3, Day 1, predose, n=6,0
    -1.035 ( 4.4739 )
    99999 ( 99999 )
        INF gamma, Session 3, Day 1, 1 hour, n=6,0
    -2.180 ( 3.8365 )
    99999 ( 99999 )
        INF gamma, Session 3, Day 1, 3 hour, n=6,0
    -3.298 ( 3.1409 )
    99999 ( 99999 )
        INF gamma, Session 3, Day 1, 6 hour, n=6,0
    -3.298 ( 3.1409 )
    99999 ( 99999 )
        INF gamma, Session 3, Day 2, n=5,0
    -2.936 ( 3.7855 )
    99999 ( 99999 )
        INF gamma, Session 3, Day 3, predose, n=6,0
    -2.948 ( 2.3737 )
    99999 ( 99999 )
        INF gamma, Session 3, Day 3, 1 hour, n=6,0
    -3.298 ( 3.1409 )
    99999 ( 99999 )
        INF gamma, Session 3, Day 3, 3 hour, n=6,0
    -3.298 ( 3.1409 )
    99999 ( 99999 )
        INF gamma, Session 3, Day 3, 6 hour, n=6,0
    -3.298 ( 3.1409 )
    99999 ( 99999 )
        INF gamma, Session 3, Day 4, n=6,0
    -3.048 ( 3.1886 )
    99999 ( 99999 )
        INF gamma, Session 3, Day 5, n=6,0
    -2.752 ( 3.2989 )
    99999 ( 99999 )
        INF gamma, Session 4, Day -2, n=5,0
    0.298 ( 5.3631 )
    99999 ( 99999 )
        INF gamma, Session 4, Day 1, predose, n=5,0
    -0.760 ( 4.2290 )
    99999 ( 99999 )
        INF gamma, Session 4, Day 1, 1 hour, n=5,0
    -1.240 ( 4.3736 )
    99999 ( 99999 )
        INF gamma, Session 4, Day 1, 3 hour, n=5,0
    -2.778 ( 3.9570 )
    99999 ( 99999 )
        INF gamma, Session 4, Day 1, 6 hour, n=5,0
    -3.274 ( 3.5110 )
    99999 ( 99999 )
        INF gamma, Session 4, Day 2, n=5,0
    -3.274 ( 3.5110 )
    99999 ( 99999 )
        INF gamma, Session 4, Day 3, predose, n=5,0
    -2.836 ( 2.6051 )
    99999 ( 99999 )
        INF gamma, Session 4, Day 3, 1 hour, n=5,0
    -3.274 ( 3.5110 )
    99999 ( 99999 )
        INF gamma, Session 4, Day 3, 3 hour, n=5,0
    -3.274 ( 3.5110 )
    99999 ( 99999 )
        INF gamma, Session 4, Day 3, 6 hour, n=5,0
    -3.274 ( 3.5110 )
    99999 ( 99999 )
        INF gamma, Session 4, Day 4, n=5,0
    -3.274 ( 3.5110 )
    99999 ( 99999 )
        INF gamma, Session 4, Day 5, n=4,0
    -2.910 ( 3.1667 )
    99999 ( 99999 )
        INF gamma, Session 5, Day -2, n=4,0
    -0.930 ( 3.5480 )
    99999 ( 99999 )
        INF gamma, Session 5, Day 1, predose, n=4,0
    -1.328 ( 2.1878 )
    99999 ( 99999 )
        INF gamma, Session 5, Day 1, 1 hour, n=4,0
    -1.423 ( 1.9828 )
    99999 ( 99999 )
        INF gamma, Session 5, Day 1, 3 hour, n=4,0
    -2.725 ( 2.8230 )
    99999 ( 99999 )
        INF gamma, Session 5, Day 1, 6 hour, n=4,0
    -3.373 ( 4.0462 )
    99999 ( 99999 )
        INF gamma, Session 5, Day 2, n=4,0
    -3.373 ( 4.0462 )
    99999 ( 99999 )
        INF gamma, Session 5, Day 3, predose, n=4,0
    0.753 ( 4.9155 )
    99999 ( 99999 )
        INF gamma, Session 5, Day 3, 1 hour, n=4,0
    0.203 ( 4.5195 )
    99999 ( 99999 )
        INF gamma, Session 5, Day 3, 3 hour, n=4,0
    -1.388 ( 4.8505 )
    99999 ( 99999 )
        INF gamma, Session 5, Day 3, 6 hour, n=4,0
    -2.838 ( 4.4804 )
    99999 ( 99999 )
        INF gamma, Session 5, Day 4, n=4,0
    -1.653 ( 6.0355 )
    99999 ( 99999 )
        INF gamma, Session 5, Day 5, n=4,0
    -0.615 ( 2.9091 )
    99999 ( 99999 )
        INF gamma, Session 6, Day -2, n=4,0
    -2.625 ( 4.4662 )
    99999 ( 99999 )
        INF gamma, Session 6, Day 1, predose, n=4,0
    -2.668 ( 4.4299 )
    99999 ( 99999 )
        INF gamma, Session 6, Day 1, 1 hour, n=4,0
    -2.823 ( 4.3091 )
    99999 ( 99999 )
        INF gamma, Session 6, Day 1, 3 hour, n=4,0
    -3.373 ( 4.0462 )
    99999 ( 99999 )
        INF gamma, Session 6, Day 1, 6 hour, n=4,0
    -3.373 ( 4.0462 )
    99999 ( 99999 )
        INF gamma, Session 6, Day 2, n=4,0
    -3.373 ( 4.0462 )
    99999 ( 99999 )
        INF gamma, Session 6, Day 3, predose, n=4,0
    -1.988 ( 5.0857 )
    99999 ( 99999 )
        INF gamma, Session 6, Day 3, 1 hour, n=4,0
    -3.018 ( 4.1848 )
    99999 ( 99999 )
        INF gamma, Session 6, Day 3, 3 hour, n=4,0
    -3.373 ( 4.0462 )
    99999 ( 99999 )
        INF gamma, Session 6, Day 3, 6 hour, n=4,0
    -3.373 ( 4.0462 )
    99999 ( 99999 )
        INF gamma, Session 6, Day 4, n=4,0
    -3.373 ( 4.0462 )
    99999 ( 99999 )
        INF gamma, Session 6, Day 5, n=4,0
    -3.373 ( 4.0462 )
    99999 ( 99999 )
        IL-12, Session 1, Day 1, predose, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-12, Session 1, Day 1, 1 hour, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-12, Session 1, Day 1, 3 hour, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-12, Session 1, Day 1, 6 hour, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-12, Session 1, Day 2, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-12, Session 1, Day 3, predose, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-12, Session 1, Day 3, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 1, Day 3, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 1, Day 3, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 1, Day 4, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 1, Day 5, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 2, Day -2, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 2, Day 1, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 2, Day 1, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 2, Day 1, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 2, Day 1, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 2, Day 2, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 2, Day 3, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 2, Day 3, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 2, Day 3, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 2, Day 3, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 2, Day 4, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 2, Day 5, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 3, Day -2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 3, Day 1, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 3, Day 1, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 3, Day 1, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 3, Day 1, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 3, Day 2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 3, Day 3, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 3, Day 3, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 3, Day 3, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 3, Day 3, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 3, Day 4, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 3, Day 5, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 4, Day -2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 4, Day 1, predose, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 4, Day 1, 1 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 4, Day 1, 3 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 4, Day 1, 6 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 4, Day 2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 4, Day 3, predose, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 4, Day 3, 1 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 4, Day 3, 3 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 4, Day 3, 6 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 4, Day 4, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 4, Day 5, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 5, Day -2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 5, Day 1, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 5, Day 1, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 5, Day 1, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 5, Day 1, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 5, Day 2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 5, Day 3, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 5, Day 3, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 5, Day 3, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 5, Day 3, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 5, Day 4, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 5, Day 5, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 6, Day -2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 6, Day 1, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 6, Day 1, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 6, Day 1, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 6, Day 1, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 6, Day 2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 6, Day 3, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 6, Day 3, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 6, Day 3, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 6, Day 3, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 6, Day 4, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-12, Session 6, Day 5, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 1, Day 1, predose, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-13, Session 1, Day 1, 1 hour, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-13, Session 1, Day 1, 3 hour, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-13, Session 1, Day 1, 6 hour, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-13, Session 1, Day 2, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-13, Session 1, Day 3, predose, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-13, Session 1, Day 3, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 1, Day 3, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 1, Day 3, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 1, Day 4, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 1, Day 5, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 2, Day -2, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 2, Day 1, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 2, Day 1, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 2, Day 1, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 2, Day 1, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 2, Day 2, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 2, Day 3, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 2, Day 3, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 2, Day 3, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 2, Day 3, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 2, Day 4, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 2, Day 5, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 3, Day -2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 3, Day 1, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 3, Day 1, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 3, Day 1, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 3, Day 1, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 3, Day 2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 3, Day 3, predose, n=6,0
    0.333 ( 0.8165 )
    99999 ( 99999 )
        IL-13, Session 3, Day 3, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 3, Day 3, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 3, Day 3, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 3, Day 4, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 3, Day 5, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 4, Day -2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 4, Day 1, predose, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 4, Day 1, 1 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 4, Day 1, 3 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 4, Day 1, 6 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 4, Day 2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 4, Day 3, predose, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 4, Day 3, 1 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 4, Day 3, 3 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 4, Day 3, 6 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 4, Day 4, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 4, Day 5, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 5, Day -2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 5, Day 1, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 5, Day 1, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 5, Day 1, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 5, Day 1, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 5, Day 2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 5, Day 3, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 5, Day 3, 1 hour, n=4,0
    0.283 ( 0.5650 )
    99999 ( 99999 )
        IL-13, Session 5, Day 3, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 5, Day 3, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 5, Day 4, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 5, Day 5, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 6, Day -2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 6, Day 1, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 6, Day 1, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 6, Day 1, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 6, Day 1, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 6, Day 2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 6, Day 3, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 6, Day 3, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 6, Day 3, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-13, Session 6, Day 4, n=4,0
    0.488 ( 0.9750 )
    99999 ( 99999 )
        IL-13, Session 6, Day 5, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 1, Day 1, predose, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-2, Session 1, Day 1, 1 hour, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-2, Session 1, Day 1, 3 hour, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-2, Session 1, Day 1, 6 hour, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-2, Session 1, Day 2, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-2, Session 1, Day 3, predose, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-2, Session 1, Day 3, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 1, Day 3, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 1, Day 3, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 1, Day 4, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 1, Day 5, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 2, Day -2, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 2, Day 1, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 2, Day 1, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 2, Day 1, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 2, Day 1, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 2, Day 2, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 2, Day 3, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 2, Day 3, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 2, Day 3, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 2, Day 3, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 2, Day 4, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 2, Day 5, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 3, Day -2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 3, Day 1, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 3, Day 1, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 3, Day 1, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 3, Day 1, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 3, Day 2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 3, Day 3, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 3, Day 3, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 3, Day 3, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 3, Day 3, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 3, Day 4, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 3, Day 5, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 4, Day -2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 4, Day 1, predose, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 4, Day 1, 1 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 4, Day 1, 3 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 4, Day 1, 6 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 4, Day 2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 4, Day 3, predose, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 4, Day 3, 1 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 4, Day 3, 3 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 4, Day 3, 6 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 4, Day 4, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 4, Day 5, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 5, Day -2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 5, Day 1, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 5, Day 1, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 5, Day 1, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 5, Day 1, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 5, Day 2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 5, Day 3, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 5, Day 3, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 5, Day 3, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 5, Day 3, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 5, Day 4, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 5, Day 5, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 6, Day -2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 6, Day 1, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 6, Day 1, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 6, Day 1, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 6, Day 1, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 6, Day 2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 6, Day 3, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 6, Day 3, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 6, Day 3, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 6, Day 3, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 6, Day 4, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-2, Session 6, Day 5, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 1, Day 1, predose, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-4, Session 1, Day 1, 1 hour, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-4, Session 1, Day 1, 3 hour, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-4, Session 1, Day 1, 6 hour, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-4, Session 1, Day 2, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-4, Session 1, Day 3, predose, n=6,1
    0.000 ( 0.0000 )
    0.000 ( 88888 )
        IL-4, Session 1, Day 3, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 1, Day 3, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 1, Day 3, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 1, Day 4, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 1, Day 5, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 2, Day -2, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 2, Day 1, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 2, Day 1, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 2, Day 1, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 2, Day 1, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 2, Day 2, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 2, Day 3, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 2, Day 3, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 2, Day 3, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 2, Day 3, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 2, Day 4, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 2, Day 5, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 3, Day -2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 3, Day 1, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 3, Day 1, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 3, Day 1, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 3, Day 1, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 3, Day 2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 3, Day 3, predose, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 3, Day 3, 1 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 3, Day 3, 3 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 3, Day 3, 6 hour, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 3, Day 4, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 3, Day 5, n=6,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 4, Day -2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 4, Day 1, predose, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 4, Day 1, 1 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 4, Day 1, 3 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 4, Day 1, 6 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 4, Day 2, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 4, Day 3, predose, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 4, Day 3, 1 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 4, Day 3, 3 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 4, Day 3, 6 hour, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 4, Day 4, n=5,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 4, Day 5, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 5, Day -2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 5, Day 1, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 5, Day 1, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 5, Day 1, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 5, Day 1, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 5, Day 2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 5, Day 3, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 5, Day 3, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 5, Day 3, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 5, Day 3, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 5, Day 4, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 5, Day 5, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 6, Day -2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 6, Day 1, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 6, Day 1, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 6, Day 1, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 6, Day 1, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 6, Day 2, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 6, Day 3, predose, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 6, Day 3, 1 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 6, Day 3, 3 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 6, Day 3, 6 hour, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 6, Day 4, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-4, Session 6, Day 5, n=4,0
    0.000 ( 0.0000 )
    99999 ( 99999 )
        IL-8, Session 1, Day 1, predose, n=6,1
    4.377 ( 5.8881 )
    1.140 ( 88888 )
        IL-8, Session 1, Day 1, 1 hour, n=6,1
    4.887 ( 12.0436 )
    0.450 ( 88888 )
        IL-8, Session 1, Day 1, 3 hour, n=6,1
    1.097 ( 6.7834 )
    0.480 ( 88888 )
        IL-8, Session 1, Day 1, 6 hour, n=6,1
    4.400 ( 9.5000 )
    8.350 ( 88888 )
        IL-8, Session 1, Day 2, n=6,1
    10.977 ( 25.4607 )
    12.720 ( 88888 )
        IL-8, Session 1, Day 3, predose, n=6,1
    6.830 ( 10.6309 )
    9.350 ( 88888 )
        IL-8, Session 1, Day 3, 1 hour, n=6,0
    3.035 ( 6.9193 )
    99999 ( 99999 )
        IL-8, Session 1, Day 3, 3 hour, n=6,0
    -0.788 ( 4.9840 )
    99999 ( 99999 )
        IL-8, Session 1, Day 3, 6 hour, n=6,0
    -0.490 ( 7.3654 )
    99999 ( 99999 )
        IL-8, Session 1, Day 4, n=6,0
    -0.542 ( 5.0480 )
    99999 ( 99999 )
        IL-8, Session 1, Day 5, n=6,0
    1.198 ( 3.0063 )
    99999 ( 99999 )
        IL-8, Session 2, Day -2, n=6,0
    7.848 ( 12.9271 )
    99999 ( 99999 )
        IL-8, Session 2, Day 1, predose, n=6,0
    4.920 ( 8.3853 )
    99999 ( 99999 )
        IL-8, Session 2, Day 1, 1 hour, n=6,0
    1.592 ( 6.9965 )
    99999 ( 99999 )
        IL-8, Session 2, Day 1, 3 hour, n=6,0
    0.275 ( 7.2669 )
    99999 ( 99999 )
        IL-8, Session 2, Day 1, 6 hour, n=6,0
    1.243 ( 6.1976 )
    99999 ( 99999 )
        IL-8, Session 2, Day 2, n=6,0
    5.468 ( 7.5652 )
    99999 ( 99999 )
        IL-8, Session 2, Day 3, predose, n=6,0
    8.322 ( 5.0082 )
    99999 ( 99999 )
        IL-8, Session 2, Day 3, 1 hour, n=6,0
    6.432 ( 10.6402 )
    99999 ( 99999 )
        IL-8, Session 2, Day 3, 3 hour, n=6,0
    -1.107 ( 5.8160 )
    99999 ( 99999 )
        IL-8, Session 2, Day 3, 6 hour, n=6,0
    -0.870 ( 4.6278 )
    99999 ( 99999 )
        IL-8, Session 2, Day 4, n=6,0
    1.667 ( 5.5170 )
    99999 ( 99999 )
        IL-8, Session 2, Day 5, n=6,0
    2.853 ( 5.4769 )
    99999 ( 99999 )
        IL-8, Session 3, Day -2, n=5,0
    12.742 ( 7.8571 )
    99999 ( 99999 )
        IL-8, Session 3, Day 1, predose, n=6,0
    7.635 ( 6.3602 )
    99999 ( 99999 )
        IL-8, Session 3, Day 1, 1 hour, n=6,0
    3.848 ( 5.5264 )
    99999 ( 99999 )
        IL-8, Session 3, Day 1, 3 hour, n=6,0
    -0.517 ( 5.6983 )
    99999 ( 99999 )
        IL-8, Session 3, Day 1, 6 hour, n=6,0
    0.933 ( 8.0166 )
    99999 ( 99999 )
        IL-8, Session 3, Day 2, n=5,0
    3.024 ( 5.5819 )
    99999 ( 99999 )
        IL-8, Session 3, Day 3, predose, n=6,0
    14.440 ( 13.4971 )
    99999 ( 99999 )
        IL-8, Session 3, Day 3, 1 hour, n=6,0
    4.887 ( 5.2130 )
    99999 ( 99999 )
        IL-8, Session 3, Day 3, 3 hour, n=6,0
    0.088 ( 4.3970 )
    99999 ( 99999 )
        IL-8, Session 3, Day 3, 6 hour, n=6,0
    2.450 ( 6.2029 )
    99999 ( 99999 )
        IL-8, Session 3, Day 4, n=6,0
    3.680 ( 4.5662 )
    99999 ( 99999 )
        IL-8, Session 3, Day 5, n=6,0
    7.783 ( 3.9382 )
    99999 ( 99999 )
        IL-8, Session 4, Day -2, n=5,0
    15.686 ( 10.4436 )
    99999 ( 99999 )
        IL-8, Session 4, Day 1, predose, n=5,0
    9.910 ( 11.2178 )
    99999 ( 99999 )
        IL-8, Session 4, Day 1, 1 hour, n=5,0
    10.088 ( 13.7154 )
    99999 ( 99999 )
        IL-8, Session 4, Day 1, 3 hour, n=5,0
    5.242 ( 11.1547 )
    99999 ( 99999 )
        IL-8, Session 4, Day 1, 6 hour, n=5,0
    6.992 ( 12.0857 )
    99999 ( 99999 )
        IL-8, Session 4, Day 2, n=5,0
    4.282 ( 8.9442 )
    99999 ( 99999 )
        IL-8, Session 4, Day 3, predose, n=5,0
    15.072 ( 11.8360 )
    99999 ( 99999 )
        IL-8, Session 4, Day 3, 1 hour, n=5,0
    10.536 ( 8.8924 )
    99999 ( 99999 )
        IL-8, Session 4, Day 3, 3 hour, n=5,0
    1.474 ( 3.3523 )
    99999 ( 99999 )
        IL-8, Session 4, Day 3, 6 hour, n=5,0
    1.208 ( 3.6252 )
    99999 ( 99999 )
        IL-8, Session 4, Day 4, n=5,0
    7.118 ( 14.6164 )
    99999 ( 99999 )
        IL-8, Session 4, Day 5, n=4,0
    -1.795 ( 4.8526 )
    99999 ( 99999 )
        IL-8, Session 5, Day -2, n=4,0
    21.055 ( 14.5161 )
    99999 ( 99999 )
        IL-8, Session 5, Day 1, predose, n=4,0
    18.213 ( 16.0292 )
    99999 ( 99999 )
        IL-8, Session 5, Day 1, 1 hour, n=4,0
    17.667 ( 15.2020 )
    99999 ( 99999 )
        IL-8, Session 5, Day 1, 3 hour, n=4,0
    12.463 ( 16.7548 )
    99999 ( 99999 )
        IL-8, Session 5, Day 1, 6 hour, n=4,0
    5.617 ( 8.7263 )
    99999 ( 99999 )
        IL-8, Session 5, Day 2, n=4,0
    5.463 ( 9.5943 )
    99999 ( 99999 )
        IL-8, Session 5, Day 3, predose, n=4,0
    16.915 ( 13.4207 )
    99999 ( 99999 )
        IL-8, Session 5, Day 3, 1 hour, n=4,0
    9.240 ( 11.0353 )
    99999 ( 99999 )
        IL-8, Session 5, Day 3, 3 hour, n=4,0
    5.902 ( 9.1992 )
    99999 ( 99999 )
        IL-8, Session 5, Day 3, 6 hour, n=4,0
    5.335 ( 7.4134 )
    99999 ( 99999 )
        IL-8, Session 5, Day 4, n=4,0
    7.610 ( 12.4139 )
    99999 ( 99999 )
        IL-8, Session 5, Day 5, n=4,0
    7.330 ( 14.2059 )
    99999 ( 99999 )
        IL-8, Session 6, Day -2, n=4,0
    12.908 ( 11.2540 )
    99999 ( 99999 )
        IL-8, Session 6, Day 1, predose, n=4,0
    17.575 ( 14.9713 )
    99999 ( 99999 )
        IL-8, Session 6, Day 1, 1 hour, n=4,0
    18.718 ( 14.2024 )
    99999 ( 99999 )
        IL-8, Session 6, Day 1, 3 hour, n=4,0
    13.823 ( 18.3486 )
    99999 ( 99999 )
        IL-8, Session 6, Day 1, 6 hour, n=4,0
    12.923 ( 15.0125 )
    99999 ( 99999 )
        IL-8, Session 6, Day 2, n=4,0
    13.338 ( 15.7070 )
    99999 ( 99999 )
        IL-8, Session 6, Day 3, predose, n=4,0
    25.338 ( 17.9965 )
    99999 ( 99999 )
        IL-8, Session 6, Day 3, 1 hour, n=4,0
    11.733 ( 12.1142 )
    99999 ( 99999 )
        IL-8, Session 6, Day 3, 3 hour, n=4,0
    6.853 ( 7.9858 )
    99999 ( 99999 )
        IL-8, Session 6, Day 3, 6 hour, n=4,0
    7.220 ( 9.8022 )
    99999 ( 99999 )
        IL-8, Session 6, Day 4, n=4,0
    13.500 ( 13.0942 )
    99999 ( 99999 )
        IL-8, Session 6, Day 5, n=4,0
    14.130 ( 9.1046 )
    99999 ( 99999 )
    Notes
    [88] - Safety Population
    [89] - Safety Population
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Non-serious AEs were collected from start of study treatment (Week 0) up to 56 days after the last dosing session (up to 265 days). SAEs were collected from start of the study treatment (Week 0) up to the end of study (Up to 369 days).
    Adverse event reporting additional description
    SAEs and non-serious AEs are reported for Safety Population for Group 1 and 2 only as no participant was enrolled in Group-3.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    21.0
    Reporting groups
    Reporting group title
    Group 2: Post-chemotherapy AL Amyloidosis participants
    Reporting group description
    Immunoglobin light chain amyloidosis (AL) participants who attained either a very good partial response (VGPR), or complete response (CR), to systemic chemotherapy (including autologous stem cell transplantation) were included. Participants received 6 anti-SAP treatments, consisting of CPHPC followed by anti-SAP mAb at monthly intervals. During each anti-SAP treatment, participants received CPHPC IV infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants were administered IV infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb was 600 mg (divided into 2 infusions of 300 mg). In each treatment session, CPHPC was administered by as SC injection for 11 days from the day of first dose of anti-SAP mAb.

    Reporting group title
    Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants
    Reporting group description
    Cardiac transthyretin (TTR) amyloidosis (transthyretin amyloid cardiomyopathy [ATTR-CM]) participants with mutant genotypes primarily associated with familial amyloidotic cardiomyopathy (FAC) and wild-type TTR were included. Participants received 6 anti-SAP treatments, consisting of carboxy pyrrolidine hexanoyl pyrrolidine carboxylate (CPHPC) followed by anti-SAP monoclonal antibody (mAb) at monthly intervals. During each anti-SAP treatment, participants received CPHPC intravenous (IV) infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants were administered intravenous infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb was 600 milligrams (mg) (divided into 2 infusions of 300 mg). In each treatment session, CPHPC was administered as subcutaneous (SC) injection for 11 days from the day of first dose of anti-SAP mAb.

    Serious adverse events
    Group 2: Post-chemotherapy AL Amyloidosis participants Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants
    Total subjects affected by serious adverse events
         subjects affected / exposed
    1 / 1 (100.00%)
    2 / 6 (33.33%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    Vascular disorders
    Vasculitis
         subjects affected / exposed
    1 / 1 (100.00%)
    0 / 6 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Cardiac failure
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Transient ischaemic attack
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Group 2: Post-chemotherapy AL Amyloidosis participants Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    1 / 1 (100.00%)
    6 / 6 (100.00%)
    Vascular disorders
    Flushing
         subjects affected / exposed
    0 / 1 (0.00%)
    3 / 6 (50.00%)
         occurrences all number
    0
    12
    Haemorrhage
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    2
    General disorders and administration site conditions
    Catheter site bruise
         subjects affected / exposed
    1 / 1 (100.00%)
    3 / 6 (50.00%)
         occurrences all number
    1
    6
    Fatigue
         subjects affected / exposed
    1 / 1 (100.00%)
    3 / 6 (50.00%)
         occurrences all number
    1
    9
    Injection site bruising
         subjects affected / exposed
    0 / 1 (0.00%)
    2 / 6 (33.33%)
         occurrences all number
    0
    2
    Oedema peripheral
         subjects affected / exposed
    0 / 1 (0.00%)
    2 / 6 (33.33%)
         occurrences all number
    0
    2
    Catheter site dermatitis
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Catheter site erythema
         subjects affected / exposed
    1 / 1 (100.00%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Catheter site related reaction
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Feeling cold
         subjects affected / exposed
    1 / 1 (100.00%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Oedema
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Peripheral swelling
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Pyrexia
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Secretion discharge
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    2
    Thirst
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    2
    Vessel puncture site bruise
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Reproductive system and breast disorders
    Nipple pain
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    0 / 1 (0.00%)
    3 / 6 (50.00%)
         occurrences all number
    0
    3
    Dyspnoea
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Dyspnoea exertional
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Oropharyngeal pain
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    0 / 1 (0.00%)
    2 / 6 (33.33%)
         occurrences all number
    0
    2
    Investigations
    Liver function test increased
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Urine output increased
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Injury, poisoning and procedural complications
    Skin laceration
         subjects affected / exposed
    0 / 1 (0.00%)
    2 / 6 (33.33%)
         occurrences all number
    0
    4
    Arthropod bite
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Limb injury
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Nail injury
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Lip injury
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Thermal burn
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Cardiac disorders
    Ventricular tachycardia
         subjects affected / exposed
    1 / 1 (100.00%)
    2 / 6 (33.33%)
         occurrences all number
    1
    33
    Cardiac failure
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Palpitations
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Ventricular extrasystoles
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Nervous system disorders
    Somnolence
         subjects affected / exposed
    1 / 1 (100.00%)
    2 / 6 (33.33%)
         occurrences all number
    1
    8
    Dizziness
         subjects affected / exposed
    0 / 1 (0.00%)
    2 / 6 (33.33%)
         occurrences all number
    0
    3
    Headache
         subjects affected / exposed
    0 / 1 (0.00%)
    2 / 6 (33.33%)
         occurrences all number
    0
    3
    Ageusia
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Depressed level of consciousness
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Paraesthesia
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Eye disorders
    Dry eye
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Ocular hyperaemia
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Gastrointestinal disorders
    Constipation
         subjects affected / exposed
    1 / 1 (100.00%)
    3 / 6 (50.00%)
         occurrences all number
    1
    5
    Abdominal discomfort
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Dyspepsia
         subjects affected / exposed
    0 / 1 (0.00%)
    2 / 6 (33.33%)
         occurrences all number
    0
    2
    Diarrhoea
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Dry mouth
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Skin and subcutaneous tissue disorders
    Rash erythematous
         subjects affected / exposed
    0 / 1 (0.00%)
    3 / 6 (50.00%)
         occurrences all number
    0
    3
    Dermatitis contact
         subjects affected / exposed
    0 / 1 (0.00%)
    2 / 6 (33.33%)
         occurrences all number
    0
    6
    Rash maculo-papular
         subjects affected / exposed
    0 / 1 (0.00%)
    2 / 6 (33.33%)
         occurrences all number
    0
    3
    Acne
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Dermal cyst
         subjects affected / exposed
    1 / 1 (100.00%)
    0 / 6 (0.00%)
         occurrences all number
    1
    0
    Erythema
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Miliaria
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Palmar erythema
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    2
    Post inflammatory pigmentation change
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Pruritus generalised
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Pruritus
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Renal and urinary disorders
    Haematuria
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Dysuria
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Urinary retention
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Musculoskeletal and connective tissue disorders
    Muscle spasms
         subjects affected / exposed
    1 / 1 (100.00%)
    1 / 6 (16.67%)
         occurrences all number
    1
    1
    Back pain
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Joint stiffness
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    2
    Joint swelling
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Limb discomfort
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Musculoskeletal stiffness
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Myalgia
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    2
    Pain in extremity
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    3
    Neck pain
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Arthralgia
         subjects affected / exposed
    0 / 1 (0.00%)
    2 / 6 (33.33%)
         occurrences all number
    0
    8
    Infections and infestations
    Nasopharyngitis
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 6 (16.67%)
         occurrences all number
    0
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    20 Apr 2017
    Amendment 1: Changes made to reflect regulatory input from the Food and Drug Administration (FDA). Other changes made to correct minor errors included in the original version.
    05 Mar 2018
    Amendment 2: Regulatory input from the FDA on clarifying requirements for recruitment. Define plasma SAP depletion target level of <3 milligrams per liter. Inclusion criterion for LV mass updated for Groups 2 and 3 to reflect the immunoglobin light chain amyloidosis (AL) participants population. Reflect regulatory safety update information for Gadolinium contrast agents. Dermatology review timings adjusted for grade 3 rash incidences. Other changes made for clarity and to correct minor typographical errors.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 14:40:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA